
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            CDK4/6 inhibitors synergize with radiotherapy to prime the tumor microenvironment and enhance the antitumor effect of anti-PD-L1 immunotherapy in triple-negative breast cancer - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4AD188AF2EC0305AD18002543DB61.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="jbiomedsci">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369063/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of Biomedical Science">
<meta name="citation_title" content="CDK4/6 inhibitors synergize with radiotherapy to prime the tumor microenvironment and enhance the antitumor effect of anti-PD-L1 immunotherapy in triple-negative breast cancer">
<meta name="citation_author" content="Wen-Chi Yang">
<meta name="citation_author_institution" content="Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, 100 Taiwan">
<meta name="citation_author_institution" content="Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan">
<meta name="citation_author_institution" content="Department of Radiation Oncology, National Taiwan University Cancer Center, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan">
<meta name="citation_author" content="Ming-Feng Wei">
<meta name="citation_author_institution" content="Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, 100 Taiwan">
<meta name="citation_author" content="Ying-Chun Shen">
<meta name="citation_author_institution" content="Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan">
<meta name="citation_author_institution" content="Department of Medical Oncology, National Taiwan University Cancer Center, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan">
<meta name="citation_author" content="Chiun-Sheng Huang">
<meta name="citation_author_institution" content="Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan">
<meta name="citation_author" content="Sung-Hsin Kuo">
<meta name="citation_author_institution" content="Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, 100 Taiwan">
<meta name="citation_author_institution" content="Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan">
<meta name="citation_author_institution" content="Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan">
<meta name="citation_author_institution" content="NTU Radiation Application and Hardness Technology Research Center, National Taiwan University, Taipei, Taiwan">
<meta name="citation_publication_date" content="2025 Aug 20">
<meta name="citation_volume" content="32">
<meta name="citation_firstpage" content="79">
<meta name="citation_doi" content="10.1186/s12929-025-01173-3">
<meta name="citation_pmid" content="40836337">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369063/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369063/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369063/pdf/12929_2025_Article_1173.pdf">
<meta name="description" content="Triple-negative breast cancer (TNBC) has the highest mortality rate among all breast cancer subtypes. Although immunotherapy shows promise, its efficacy varies. CDK4/6 inhibitors can radiosensitize and modulate the immune system, and high-dose ...">
<meta name="og:title" content="CDK4/6 inhibitors synergize with radiotherapy to prime the tumor microenvironment and enhance the antitumor effect of anti-PD-L1 immunotherapy in triple-negative breast cancer">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Triple-negative breast cancer (TNBC) has the highest mortality rate among all breast cancer subtypes. Although immunotherapy shows promise, its efficacy varies. CDK4/6 inhibitors can radiosensitize and modulate the immune system, and high-dose ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369063/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12369063">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s12929-025-01173-3"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/12929_2025_Article_1173.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12369063%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12369063/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12369063/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369063/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-jbiomedsci.png" alt="Journal of Biomedical Science logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Journal of Biomedical Science" title="Link to Journal of Biomedical Science" shape="default" href="https://jbiomedsci.biomedcentral.com/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Biomed Sci</button></div>. 2025 Aug 20;32:79. doi: <a href="https://doi.org/10.1186/s12929-025-01173-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s12929-025-01173-3</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22J%20Biomed%20Sci%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Biomed%20Sci%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Biomed%20Sci%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Biomed%20Sci%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>CDK4/6 inhibitors synergize with radiotherapy to prime the tumor microenvironment and enhance the antitumor effect of anti-PD-L1 immunotherapy in triple-negative breast cancer</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yang%20WC%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Wen-Chi Yang</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Wen-Chi Yang</span></h3>
<div class="p">
<sup>1</sup>Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, 100 Taiwan </div>
<div class="p">
<sup>2</sup>Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan </div>
<div class="p">
<sup>3</sup>Department of Radiation Oncology, National Taiwan University Cancer Center, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yang%20WC%22%5BAuthor%5D" class="usa-link"><span class="name western">Wen-Chi Yang</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wei%20MF%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Ming-Feng Wei</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Ming-Feng Wei</span></h3>
<div class="p">
<sup>1</sup>Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, 100 Taiwan </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wei%20MF%22%5BAuthor%5D" class="usa-link"><span class="name western">Ming-Feng Wei</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shen%20YC%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Ying-Chun Shen</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Ying-Chun Shen</span></h3>
<div class="p">
<sup>2</sup>Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan </div>
<div class="p">
<sup>4</sup>Department of Medical Oncology, National Taiwan University Cancer Center, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Shen%20YC%22%5BAuthor%5D" class="usa-link"><span class="name western">Ying-Chun Shen</span></a>
</div>
</div>
<sup>2,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20CS%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Chiun-Sheng Huang</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Chiun-Sheng Huang</span></h3>
<div class="p">
<sup>5</sup>Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Huang%20CS%22%5BAuthor%5D" class="usa-link"><span class="name western">Chiun-Sheng Huang</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kuo%20SH%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Sung-Hsin Kuo</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Sung-Hsin Kuo</span></h3>
<div class="p">
<sup>1</sup>Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, 100 Taiwan </div>
<div class="p">
<sup>2</sup>Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan </div>
<div class="p">
<sup>6</sup>Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan </div>
<div class="p">
<sup>7</sup>NTU Radiation Application and Hardness Technology Research Center, National Taiwan University, Taipei, Taiwan </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kuo%20SH%22%5BAuthor%5D" class="usa-link"><span class="name western">Sung-Hsin Kuo</span></a>
</div>
</div>
<sup>1,</sup><sup>2,</sup><sup>6,</sup><sup>7,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, No. 7, Chung-Shan South Road, Taipei, 100 Taiwan </div>
<div id="Aff2">
<sup>2</sup>Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan </div>
<div id="Aff3">
<sup>3</sup>Department of Radiation Oncology, National Taiwan University Cancer Center, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan </div>
<div id="Aff4">
<sup>4</sup>Department of Medical Oncology, National Taiwan University Cancer Center, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan </div>
<div id="Aff5">
<sup>5</sup>Department of Surgery, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan </div>
<div id="Aff6">
<sup>6</sup>Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan </div>
<div id="Aff7">
<sup>7</sup>NTU Radiation Application and Hardness Technology Research Center, National Taiwan University, Taipei, Taiwan </div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 May 22; Accepted 2025 Aug 12; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a>. The Creative Commons Public Domain Dedication waiver (<a href="https://creativecommons.org/publicdomain/zero/1.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12369063  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40836337/" class="usa-link">40836337</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p id="Par1">Triple-negative breast cancer (TNBC) has the highest mortality rate among all breast cancer subtypes. Although immunotherapy shows promise, its efficacy varies. CDK4/6 inhibitors can radiosensitize and modulate the immune system, and high-dose radiotherapy (RT) can enhance the effects of immunotherapy. This study explored the combination of RT with CDK4/6 inhibitors to improve TNBC immunotherapy by modulating the tumor microenvironment.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">We assessed the radiosensitizing effects of abemaciclib (a CDK4/6 inhibitor) using clonogenic assays in three human TNBC cell lines (MDA-MB-231, MDA-MB-453, and MDA-MB-468) and two murine TNBC cell lines (4T1 and EMT6). The antitumor efficacy of the treatments (control, RT, abemaciclib, anti-PD-L1 antibody [aPD-L1], abemaciclib combined with aPD-L1, abemaciclib combined with RT, aPD-L1 combined with RT, and the triple combination of abemaciclib with aPD-L1 and RT) was evaluated in both 4T1 and EMT6 cell line-derived immunocompetent mouse models. Interferon-γ (IFN-γ) levels in mouse blood were monitored to gauge the immune response. Tumor-infiltrating lymphocytes (TILs) were analyzed using flow cytometry and immunohistochemical staining.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">Clonogenic assays showed synergistic effects of RT and abemaciclib in all TNBC cell lines. RT increased PD-L1 expression, whereas abemaciclib did not alter PD-L1 expression. In the 4T1 and EMT6 mouse models, the triple combination treatment markedly inhibited tumor growth (<em>P</em> &lt; 0.01). In the 4T1 mouse model, the triple combination group exhibited significantly greater circulating IFN-γ levels (<em>P</em> &lt; 0.001) than the other groups. TIL analysis revealed a significant increase in CD4 + and CD8 + T cells and tumor-associated macrophages (<em>P</em> &lt; 0.01) in the triple combination therapy group. Immunohistochemical staining confirmed increased infiltration of CD4 + T cells, CD8 + T cells, monocyte chemoattractant protein-1, CD80-, and iNOS- positive macrophages into the tumor microenvironment of this group, with a marked reduction in CD206-positive macrophages.</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusion</h3>
<p id="Par4">Combining CDK4/6 inhibitors with RT enhanced the antitumor effects of aPD-L1 immunotherapy against TNBC. This effect was correlated with increased IFN-γ secretion and recruitment of CD4 + and CD8 + T cells and M1 tumor-associated macrophages, leading to modulation of the tumor microenvironment.</p></section><section id="sec5"><h3 class="pmc_sec_title">Supplementary Information</h3>
<p>The online version contains supplementary material available at 10.1186/s12929-025-01173-3.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> CDK4/6 inhibitor, Radiotherapy, Immunotherapy</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Background</h2>
<p id="Par38">Breast cancer represents the most common cancer among women globally, classified into subtypes based on molecular characteristics that remarkably influence prognosis [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. Among these, triple-negative breast cancer (TNBC) stands out due to its aggressive nature and a lack of well-defined molecular targets, contributing to poorer outcomes than those in the other three subtypes [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>, <a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>].</p>
<p id="Par39">The advent of immunotherapy has revolutionized oncological treatment, with immune checkpoint inhibitors (ICIs) emerging as promising treatment options. However, recent studies have demonstrated that the distinct genetic subtypes of TNBCs have a unique tumor microenvironment, impacting the effectiveness of immune responses to treatment [<a href="#CR4" class="usa-link" aria-describedby="CR4">4</a>]. Single-agent anti-PD-L1 therapies, such as atezolizumab, have demonstrated limited efficacy in patients with TNBC [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. Combining ICIs with other anti-cancer treatments has yielded more potent responses, possibly due to increased antigenicity and adjuvanticity [<a href="#CR6" class="usa-link" aria-describedby="CR6">6</a>]. Notably, neoadjuvant chemotherapy combined with pembrolizumab has achieved higher rates of pathological complete response in early TNBC than chemotherapy alone [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>], highlighting the need for combination therapies in enhancing immune response.</p>
<p id="Par40">Cyclin D-cyclin-dependent kinase 4 and 6 (CDK4/6) are pivotal regulators of cell cycle progression, explicitly facilitating transition from the G1 to S phase. Given their crucial role in cell proliferation, CDK4/6 s have emerged as promising therapeutic targets in cancer treatment [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>]. In breast cancer, the CDK4/6-cyclin D axis plays a significant role in tumorigenesis [<a href="#CR9" class="usa-link" aria-describedby="CR9">9</a>, <a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>], with cyclin D1 frequently overexpressed, particularly in estrogen receptor (ER)-positive cases [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>].</p>
<p id="Par41">A previous preclinical study demonstrated that CDK4/6 inhibitors could inhibit tumors in non-luminal cell lines [<a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>]. Despite frequent retinoblastoma (RB) loss that can make patients with TNBC poor candidates for receiving CDK4/6 inhibitors, some studies have shown that TNBC cell lines are sensitive to CDK inhibition in vitro and in vivo [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>, <a href="#CR14" class="usa-link" aria-describedby="CR14">14</a>]. A randomized phase II trial by Tan et al<em>.</em> demonstrated that patients receiving trilaciclib, a CDK4/6 inhibitor, alongside chemotherapy achieved better progression-free and overall survival compared to those receiving chemotherapy alone [<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>], suggesting the potential application of CDK4/6 inhibitors in TNBC treatment.</p>
<p id="Par42">CDK4/6 inhibitors promote cytotoxic T-cell activity and increase tumor antigen presentation, potentially improving immunotherapy efficacy [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]. Clinical trials, such as the neoMONARCH phase II neoadjuvant study, have also demonstrated upregulation of inflammatory and T-cell-related pathways following treatment with abemaciclib and anastrozole, supporting their potential immune regulation effects in the clinical practice [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>].</p>
<p id="Par43">Radiotherapy (RT) is a common treatment strategy for solid cancers, including breast cancer [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. High-dose RT exhibits immunogenic properties, acting as an in situ tumor vaccine by stimulating the release of tumor-associated antigen, recruiting cytotoxic T lymphocytes, and enhancing the abscopal effect [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. Ho et al. conducted an early phase II trial that combined pembrolizumab with hypofractionated RT in patients with metastatic TNBC [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]. The overall response rate was 17.6% in the entire cohort, with three patients achieving complete response outside the radiation field [<a href="#CR20" class="usa-link" aria-describedby="CR20">20</a>]. Early preclinical models have reported synergistic effects between RT and CDK4/6 inhibitors in various cancers, suggesting that combining these treatments could enhance cytotoxicity and potentially modulate the immune response [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>, <a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>].</p>
<p id="Par44">To identify the best synergistic treatment combination for TNBC, we investigated the effectiveness of combining CDK4/6 inhibitors, RT, and ICIs. TNBC is an aggressive and heterogeneous cancer with limited response to single-agent ICIs such as pembrolizumab and atezolizumab [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>, <a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. However, combining ICIs with chemotherapy has resulted in improved outcomes, underscoring the need for exploring combination therapies. CDK4/6 inhibitors not only induce cell cycle arrest but also enhance immune responses by promoting cytotoxic T-cell activity. Similarly, RT boosts immunogenicity by stimulating the release of tumor-associated antigens and recruiting cytotoxic T lymphocytes [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>]. Therefore, the combination of a CDK4/6 inhibitor, RT, and ICIs represents a promising approach for TNBC treatment. In the present study, we used a poorly immunogenic and highly metastatic 4T1 mouse model [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>, <a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>] and a relatively immunogenic EMT6 mouse model [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>] to mimic advanced human TNBC and thereby investigate whether combining CDK4/6 inhibitors with RT can improve the efficacy of anti-PD-L1 immunotherapy in 4T1- and EMT6- derived immunocompetent mouse models.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Breast cancer cell lines and cell culture</h3>
<p id="Par45">We used three human TNBC cell lines and two murine TNBC cell lines from the American Type Culture Collection (ATCC) (Rockville, Maryland, USA). These human TNBC cell lines, included MDA-MB-231 (ATCC® HTB-26™), MDA-MB-453 (ATCC® HTB-131™), and MDA-MB-468 (ATCC® HTB-132™). We also used two murine TNBC cell lines, including 4T1 (ATCC® CRL-2539™) and EMT6 (ATCC® CRL-2755™). All TNBC cell lines were cultured at 37 °C with 5% atmospheric CO<sub>2</sub> following the manufacturer’s guidelines for maintenance. The MDA-MB-453, MDA-MB-468, and 4T1 cell lines were cultured in Gibco Roswell Park Memorial Institute 1640 medium, while the MDA-MB-231 cell line was grown in Dulbecco’s modified Eagle’s medium, and the EMT6 cell line was grown in Waymouth’s MB 752/1 medium.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Drugs and ionizing irradiation</h3>
<p id="Par46">This study investigated the effects of abemaciclib, a CDK4/6 inhibitor, on cellular functions and its potential antitumor activity. Abemaciclib was purchased from a commercial supplier, MedChemExpress (MCE<em>,</em> Shanghai, China), prepared as a stock solution in 100% DMSO at a concentration of 10 mmol/L. Ionizing radiation treatment was delivered using a Caesium-137 (Cs137) irradiator (IBL 637, CIS Bio International, Saclay, France) [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>] at a dose rate around 3 Gy/min to whole body with 5 mm lead shielding applied to protect the non-target areas. Additionally, the efficacy of immunotherapy was evaluated in vivo using an anti-mouse PD-L1 antibody (catalog number BE0101, BioCell).</p>
<p id="Par47">Abemaciclib was applied in vitro at 100–200 nM—approximately ≤ 10% of the half-maximal inhibitory concentration (IC<sub>50</sub>), for inhibiting proliferation of our TNBC cell lines (Supplementary Fig. 1)—to permit radiosensitization read-outs without confounding effects from direct cytotoxicity [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. TNBC cells were irradiated with a single dose of 8 Gy or 16 Gy, administered 1 h after drug treatment. These high single fraction RT doses are widely used to induce DNA damage, upregulate PD-L1 expression, and modulate the immune response [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>].</p></section><section id="Sec5"><h3 class="pmc_sec_title">Cell proliferation assay</h3>
<p id="Par48">The five TNBC cell lines (MDA-MB-231, MDA-MB-453, MDA-MB-468, 4T1, and EMT6) were seeded in 96-well plates at 1000 cells per well in 100 μL medium. Subsequently, the cells were treated with varying concentrations of abemaciclib. In the present study, we assessed cell proliferation 3 days after treatment using the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, Wisconsin, USA). Absorbance readings were obtained at 450 nm using a multi-well plate reader, with a background control for comparison. The IC<sub>50</sub> of abemaciclib for each cell line was determined based on these measurements.</p></section><section id="Sec6"><h3 class="pmc_sec_title">Clonogenic assay</h3>
<p id="Par49">The TNBC cell lines MDA-MB-231, MDA-MB-453, MDA-MB-468, 4T1, and EMT6 were cultured in individual wells of six-well plates, with each well containing 2,000 cells. These cells were subjected to various doses of RT, ranging from 0 to 6 Gy, and treated with different concentrations of abemaciclib 1 h prior to RT. The culture medium was maintained until the end of the study. After 7–14 days, the colonies in each well were counted using an inverted phase-contrast microscope at a magnification of 100 ×. A colony was defined as a cluster of more than 50 cells. To assess the synergistic effect of the combined treatments, the combination index (CI) was determined using the Chou–Talalay equation [<a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>].</p></section><section id="Sec7"><h3 class="pmc_sec_title">Flow cytometry</h3>
<p id="Par50">To assess PD-L1 surface expression, MDA-MB-231, MDA-MB-453, MDA-MB-468, 4T1, and EMT6 cells were exposed to various doses of RT and abemaciclib and harvested after 24 h. The cells were then stained with an anti-PD-L1 antibody (aPD-L1) (#13684; Cell Signaling Technology) for analysis using an LSR II flow cytometer (BD Biosciences, San Diego, CA, USA). To examine tumor-infiltrating lymphocytes (TILs), single-cell suspensions were prepared from tumors dissected from the 4T1 cell line-derived xenograft immunocompetent mice. These cells were stained with fluorochrome-conjugated antibodies targeting CD45 (cat. 536,709, BD Biosciences), CD4 (cat. 553051, BD Biosciences), CD8 (cat. 552877, BD Biosciences), CD11b (cat. 564985, BD Biosciences), GR-1 (cat. 552093, BD Biosciences), F4/80 (cat. 565613, BD Biosciences), Foxp3 (cat. 12-5774-83, eBiosciences), Ly6C (cat. 562737, BD Horizon™), Ly6G (cat. 563011, BD Horizon™), and isotype control RatIgG2a (cat. 12-4321-80, eBiosciences). We distinguished live cells from dead using the LIVE/DEAD™ Fixable Green Dead Cell Stain Kit (cat. <a href="https://www.ncbi.nlm.nih.gov/nuccore/L23101" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">L23101</a>, Invitrogen, Waltham, MA). For intracellular markers, cells were fixed and permeabilized with specific solutions (eBiosciences, San Diego, CA, USA) at room temperature for 30 min (extended to 60 min for Foxp3 staining), with a gating set using matched isotype controls. The LSR II flow cytometer (BD Biosciences, San Diego, CA, USA) facilitated the analysis, and all flow cytometry data were processed using FlowJo 10.1 software (Ashland, OR, USA).</p></section><section id="Sec8"><h3 class="pmc_sec_title">Western blotting</h3>
<p id="Par51">Protein samples from MDA-MB-231, MDA-MB-453, MDA-MB-468, 4T1 and EMT6 cells were harvested following treatment with the control, RT, abemaciclib, or a combination of abemaciclib and RT. Mammalian protein extraction reagent (M-PER; Pierce, Rockford, IL, USA) was used for protein extraction. Equal amounts of protein extracted from each cell line were separated via electrophoresis on 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis gels using the Tris–glycine buffer system. The separated proteins were transferred onto nitrocellulose membranes (Novex, San Diego, CA, USA) and blocked overnight in 1 × Tris-buffered saline supplemented with 0.1% Tween-20 and 5% nonfat dry milk. The membranes were then probed with primary antibodies against RB (#9309S, Cell Signaling Technology), phosphorylated RB (#8516S, Cell Signaling Technology), and α-tubulin (#2144, Cell Signaling Technology). Following incubation with secondary antibodies, the protein bands were visualized using an enhanced chemiluminescence detection system (Boehringer Mannheim, Germany). Each experiment was conducted at least thrice to ensure reliability.</p></section><section id="Sec9"><h3 class="pmc_sec_title">Enzyme-linked immunosorbent assay (ELISA)</h3>
<p id="Par52">Serum samples from 4T1 mouse model were analyzed for interferon-gamma (IFN-γ) levels using the Quantikine™ ELISA Mouse IFN-γ Immunoassay kit (cat. MIF00-1; Sigma-Aldrich) following the manufacturer’s protocol for reagent preparation. The assay procedure involved the sequential addition of assay diluent, standards, controls, or samples to the wells, followed by a 2 h incubation at room temperature. After a thorough washing step, mouse IFN-γ conjugates were added, and the plates were incubated for an additional 2 h. Subsequently, a substrate solution was added, and the plates were shielded from light. The optical density at 450 nm of each well was measured using a microplate reader, and this optical density was used to calculate the concentration of IFN-γ present in the samples.</p></section><section id="Sec10"><h3 class="pmc_sec_title">In vivo mice model</h3>
<p id="Par53">Female BALB/c mice aged 5–6 weeks were obtained from the National Laboratory Animal Center, Taiwan, and the experimental procedures were approved by the Institutional Animal Care and Use Committee of the National Taiwan University (IACUC Number 20210366). Each mouse received a 100 µL subcutaneous injection of prepared 4T1 or EMT6 cells at a concentration of 1 × 10<sup>5</sup> cells/mL at flank. Tumor volumes were calculated using the following formula: π/6 × length × width × height, with “length,” “width,” and “height” representing the tumor’s respective dimensions. Upon reaching an average tumor volume of approximately 100 mm<sup>3</sup>, the mice were divided into eight treatment groups: control (PBS for anti-PD-L1, DMSO for Abemaciclib), RT alone, abemaciclib alone, aPD-L1 alone, abemaciclib combined with aPD-L1, abemaciclib combined with RT, aPD-L1 combined with RT, and abemaciclib combined with aPD-L1 and RT.</p>
<p id="Par54">Tumor irradiation was performed using a Cs137 irradiator, delivering 8 Gy weekly for two weeks to maximize immunogenic cell death and limit normal tissue injury; hypofractionated RT schedules of approximately 8–10 Gy per fraction have been shown to potentiate systemic immune responses and synergize with immune checkpoint blockade [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>, <a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>]. Abemaciclib was administered orally daily for two weeks at 50 mg/kg as commonly suggested and well tolerated [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>, <a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>], a regimen that achieves peak plasma levels of approximately 1.5 µg/mL and a terminal half-life of approximately 44 h, mirroring efficacious exposures in patients while maintaining good tolerability [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. The anti-mouse PD-L1 antibody (aPD-L1) was given 200 μg per mouse (which approximately 10 mg/kg) via intraperitoneal route three times a week as recommended [<a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>].</p>
<p id="Par55">Drug administration was followed by irradiation for 1 h [<a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>]. Serum samples were collected one day before treatment, during the second week of treatment, and in the third week (post-treatment) to measure IFN-γ levels, as previously described. After euthanasia, the tumors were excised for further analysis, including flow cytometry for quantifying TILs and immunohistochemistry (IHC).</p></section><section id="Sec11"><h3 class="pmc_sec_title">Immunohistochemistry staining</h3>
<p id="Par56">Tumor specimens from mice were initially rinsed with phosphate-buffered saline (PBS) and subsequently fixed in 4% formaldehyde (Mallinckrodt Chemical Co., St. Louis, MO, USA) diluted in PBS. After fixation, the specimens were embedded in paraffin. Sections of 6 µm thickness were then prepared from the paraffin-embedded tissues. The sections were deparaffinized before application of primary antibodies for IHC staining [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]. The primary antibodies used were against CD4 (HS-360 117, Sysy), CD8 (HS-361 003, Sysy), monocyte chemotactic protein-1 (MCP-1, a marker of M1 macrophages; orb323291, Biorbyt) [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>], CD80 (a marker of M1 macrophages; HPA050092, Sigma-Aldrich) [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>], inducible nitric oxide synthase (iNOS, a marker of M1 macrophages; PA3-030A, ThermoFisher) [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>], and CD206 (a marker of M2 macrophages; ab64693, Abcam) [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>]. Antigens were visualized using an indirect immunoperoxidase technique following the manufacturer’s protocol.</p></section><section id="Sec12"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par57">All experiments were performed independently at least three times to ensure reproducibility. Results are expressed as the mean ± standard deviation (SD). Details of the statistical tests used for each dataset are provided in the corresponding figure legends. Statistical significance was set at <em>P</em> &lt; 0.05, with significance levels indicated as follows: * <em>P</em> &lt; 0.05, ** <em>P</em> &lt; 0.01, *** <em>P</em> &lt; 0.001, and **** <em>P</em> &lt; 0.0001. Error bars in the figures denote SD. Statistical analyses and graph generation were conducted using GraphPad Prism (version 9.5.1, GraphPad Software, Inc., Windows).</p></section></section><section id="Sec13"><h2 class="pmc_sec_title">Results</h2>
<section id="Sec14"><h3 class="pmc_sec_title">CDK4/6 inhibitors have anti-tumor effects in TNBC cell lines</h3>
<p id="Par58">To evaluate the effectiveness of the CDK4/6 inhibitor, abemaciclib, in TNBC cell lines, we assessed the viability of MDA-MB-231, MDA-MB-453, and MDA-MB-468 cells treated with different doses of abemaciclib. The IC<sub>50</sub> values for abemaciclib were found to be 12.15, 2.86, and 8.01 µM for MDA-MB-231, MDA-MB-453, and MDA-MB-468 cells, respectively; the corresponding cell survival curves are presented in Supplementary Fig. 1.</p>
<p id="Par59">CDK4/6 plays a critical role in cell cycle progression from the G1 to the S phase by phosphorylating RB, subsequently releasing the E2F transcription factor [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>]. We investigated RB expression in five cell lines using western blot analysis (Supplementary Fig. 2). Cells were treated with either a control, 4 Gy of RT, 50 nM abemaciclib, or a combination of RT and abemaciclib. The levels of RB and phosphorylated RB (p-RB) were assessed after 24 h of treatment. All cell lines demonstrated RB expression, our findings revealed that abemaciclib effectively inhibited phosphorylation of RB, as evidenced by reduced levels of p-RB, whereas RT did not significantly alter p-RB levels (Supplementary Fig. 2).</p></section><section id="Sec15"><h3 class="pmc_sec_title">CDK4/6 inhibitor sensitizes TNBC cells to ionizing irradiation</h3>
<p id="Par60">Radiosensitization effect have been investigated in luminal type breast cancer and other cancer types as well [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>, <a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>]. To confirm the combined benefits of RT and CDK4/6 inhibitors in TNBC treatment, the radiosensitizing effects of abemaciclib on TNBC cell lines were tested. A clonogenic assay was performed to assess whether abemaciclib can enhance the sensitivity of TNBC cell lines to RT. MDA-MB-231, MDA-MB-453, MDA-MB-468, 4T1 and EMT6 cells were pretreated with various doses of abemaciclib (0–80 nM for MDA-MB-231, MDA-MB-453, and MDA-MB-468; 0–400 nM for 4T1, and 0–800 nM EMT6) for 1 h before exposure to different doses of RT (0–4 Gy for MDA-MB-231, MDA-MB-453, and MDA-MB-468; 0–6 Gy for 4T1 and EMT6). A significant synergistic effect between abemaciclib and RT was observed in all five cell lines, demonstrating a dose-dependent radiosensitization effect, as illustrated in Fig. <a href="#Fig1" class="usa-link">1</a>. Colony survival data were plotted using a linear quadratic model via nonlinear regression, as detailed in Fig. <a href="#Fig1" class="usa-link">1</a>A–E. Higher dose of abemaciclib demonstrated significantly better radiosensitization effect across five cell lines (<em>P</em> &lt; 0.05).</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369063_12929_2025_1173_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2aba/12369063/0a43ce3569c5/12929_2025_1173_Fig1_HTML.jpg" loading="lazy" id="MO1" height="980" width="784" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Abemaciclib synergizes with radiation therapy (RT) to significantly reduce the survival of triple-negative breast cancer cell lines, as demonstrated through colony-formation assays. Clonogenic assay results for (<strong>A</strong>) MDA-MB-231, (<strong>B</strong>) MDA-MB-453, (<strong>C</strong>) MDA-MB-468, (<strong>D</strong>) 4T1, and (<strong>E</strong>) EMT6 cells treated with varying doses of abemaciclib (0–40 nM for MDA-MB-231, 0–20 nM for MDA-MB-453, 0–80 nM for MDA-MB-468, 0–400 nM for 4T1, and 0–800 nM for EMT-6) and RT (0–6 Gy). Abemaciclib was administered 1 h before RT. Colonies were fixed, stained, and counted after 7–14 days. The left columns display the surviving fractions of all five cell lines fitted to a linear quadratic model. The middle columns represent the average number of colonies and their standard deviations. The right columns show photographs of the colonies, illustrating the effects of combining various RT doses with different concentrations of abemaciclib on the five TNBC cell lines. All experiments were conducted at least three times. Statistical analysis was conducted using two-way analysis of variance (ANOVA) with Tukey’s post-hoc test. Significance levels: *<em>P</em> &lt; 0.05; **<em>P</em> &lt; 0.01</p></figcaption></figure></section><section id="Sec16"><h3 class="pmc_sec_title">Radiotherapy increases cell surface PD-L1 expression in TNBC cells</h3>
<p id="Par61">Both RT and CDK4/6 inhibitors have been recognized for their immunomodulatory effects [<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>–<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>], prompting investigations to determine whether their combination can enhance the efficacy of anti-PD-L1 therapy. The present study evaluated the influence of RT and abemaciclib, both alone and in combination, on the expression of PD-L1 on the cell surface. MDA-MB-231, MDA-MB-453, MDA-MB-468, 4T1, and EMT6 cells were treated with varying doses of RT (0, 8, or 16 Gy), abemaciclib (0, 100, or 200 nM) alone, or a combination of 8 Gy RT and abemaciclib pretreatment (100 or 200 nM) 1 h before RT. Our findings revealed that RT at 8 and 16 Gy notably increased PD-L1 expression in all five cell lines (Fig. <a href="#Fig2" class="usa-link">2</a>A and <a href="#Fig2" class="usa-link">D</a>). In contrast, abemaciclib alone did not affect the surface expression of PD-L1 (Fig. <a href="#Fig2" class="usa-link">2</a>B and <a href="#Fig2" class="usa-link">D</a>). Combining RT with abemaciclib mirrored the effects of RT alone on PD-L1 expression, suggesting that abemaciclib did not alter the RT-induced modulation of PD-L1 expression (Fig. <a href="#Fig2" class="usa-link">2</a>C and <a href="#Fig2" class="usa-link">D</a>). These results indicate that the combination of RT and abemaciclib did not enhance or diminish the individual effects of RT on PD-L1 expression levels.</p>
<figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369063_12929_2025_1173_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2aba/12369063/f90448ae2c6b/12929_2025_1173_Fig2_HTML.jpg" loading="lazy" id="MO2" height="804" width="784" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Surface PD-L1 expression in triple negative breast cancer cell lines under different doses of RT and abemaciclib. MDA-MB-231, MDA-MB-453, MDA-MB-468, 4T1, and EMT6 cells were treated with (<strong>A</strong>) different doses of RT (8 Gy, 16 Gy, or no RT), (<strong>B</strong>) different doses of abemaciclib (100 nM, 200 nM, or without abemaciclib), or (<strong>C</strong>) RT (8 Gy) in combination with abemaciclib at 100 nM or 200 nM, or without any treatment. The cells were collected 24 h after treatment. Subsequently, all cells were stained with an anti-PD-L1 antibody and analyzed using a LSR II flow cytometer (BD Biosciences, San Diego, CA). <strong>D</strong> Mean fluorescence intensity (MFI) bar charts quantify PD-L1 expression levels under each condition and presented as mean ± standard deviation. The difference in MFI values was assessed by an unpaired two-tailed t-test. All experiments were conducted three times. Significance levels: *<em>P</em> &lt; 0.05; **<em>P</em> &lt; 0.01; ***<em>P</em> &lt; 0.001, ****<em>P</em> &lt; 0.0001</p></figcaption></figure></section><section id="Sec17"><h3 class="pmc_sec_title">CDK4/6 inhibitor combined with RT enhances anti-PD-L1 efficacy in vivo of TNBC</h3>
<p id="Par62">Although CDK4/6 inhibitors do not significantly elevate cell surface PD-L1 expression like RT, they possess immunomodulatory effects that can potentiate immunotherapy [<a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>, <a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>, <a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>]. Additionally, high-dose RT is widely acknowledged for boosting immune responses and enhancing the efficacy of immunotherapy [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>, <a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>]. In the present study, we aimed to evaluate the synergistic effects of combining RT with CDK4/6 inhibitors and anti-PD-L1 antibodies on tumor suppression in vivo using 4T1 and EMT6 immunocompetent mouse models. Mice were divided into eight treatment groups: control, RT alone, abemaciclib alone, aPD-L1 alone, abemaciclib combined with aPD-L1, abemaciclib combined with RT, aPD-L1 combined with RT, and abemaciclib combined with aPD-L1 and RT. The various treatment strategies are detailed in Fig. <a href="#Fig3" class="usa-link">3</a>A. Over a two-week treatment period, tumor sizes were monitored twice a week. There is no significant difference between mice weights during and after treatment in different treatment groups (Fig. <a href="#Fig3" class="usa-link">3</a>B). The mice were euthanized after one to two weeks of follow-up till tumor volume exceed 1500–2000 mm<sup>3</sup>. The tumors were excised and their volumes were analyzed. The data are presented in Fig. <a href="#Fig3" class="usa-link">3</a>B and <a href="#Fig3" class="usa-link">C</a>. We found that the group receiving the combination treatment of abemaciclib, aPD-L1, and RT exhibited a significant reduction in tumor growth compared to all other groups (all, <em>P</em> &lt; 0.05). Additionally, tumors excised from the triple combination group showed significantly lower weight than those from the control group in both 4T1 (<em>P</em> &lt; 0.001) and EMT6 murine models (<em>P</em> &lt; 0.0001), as depicted in Fig. <a href="#Fig3" class="usa-link">3</a>C. When compared with other groups, the tumor weights of the triple combination group were still lower (all, <em>P</em> &lt; 0.05). We found that no significant difference was observed in tumor growth between single-modality treatments (RT alone, abemaciclib alone, or aPD-L1 alone) and dual treatments such as abemaciclib combined with aPD-L1, abemaciclib combined with RT, or aPD-L1 combined with RT. This highlights the enhanced efficacy of the triple combination in comparison with single or dual treatments. These findings suggest that the combination of abemaciclib and RT significantly enhanced the antitumor efficacy of aPD-L1 in comparison with the other treatment arms. We examined lung metastases and found no significant differences among the treatment groups. This observation suggests that while the treatments effectively control primary tumor growth, their impact on metastatic progression requires further investigation.</p>
<figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369063_12929_2025_1173_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2aba/12369063/56e913aa1e63/12929_2025_1173_Fig3_HTML.jpg" loading="lazy" id="MO3" height="938" width="783" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Antitumor effect of different combinations of RT, abemaciclib, and anti-PD-L1 antibody (aPD-L1) in vivo. <strong>A</strong> 4T1 and EMT6 mouse models were used with female BALB/c mice for the in vivo study. The schematic diagram of the therapeutic protocol is shown. Eight mice were included in each group. <strong>B</strong> The tumor volume and body weight of the two mouse models treated with RT, abemaciclib, aPD-L1, or their dual and triple combinations. The tumor volume and body weight were measured twice a week during the treatment period. The tumor volume difference was assessed by two-way analysis of variance (ANOVA) with mixed-effect analysis. <strong>C</strong> After euthanasia, the tumors were excised and weighed. The excised tumor weight difference was assessed by an unpaired two-tailed t-test. Significance levels: *<em>P</em> &lt; 0.05; **<em>P</em> &lt; 0.01; ***<em>P</em> &lt; 0.001, ****<em>P</em> &lt; 0.0001</p></figcaption></figure></section><section id="Sec18"><h3 class="pmc_sec_title">CDK4/6 inhibitor, RT, and anti-PD-L1 increase circulating IFN-γ levels</h3>
<p id="Par63">We also monitored the changes in immune-related cytokines throughout the treatment period in all the groups. IFN-γ, a pivotal cytokine in the immune response, serves as a biomarker that reflects the efficacy of immunotherapy. IFN-γ is known to be upregulated by checkpoint inhibitors, highlighting their role in immune surveillance and therapeutic responses [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]. Therefore, we evaluated the circulating IFN-γ levels in our 4T1 mouse model.</p>
<p id="Par64">Blood samples were collected from mice before, during, and after treatment, and IFN-γ levels were measured using ELISA. Figure <a href="#Fig4" class="usa-link">4</a> displays the changes in circulating IFN-γ levels before, during, and after treatment for each treatment group. In the control (Fig. <a href="#Fig4" class="usa-link">4</a>A), abemaciclib (Fig. <a href="#Fig4" class="usa-link">4</a>C), and aPD-L1 (Fig. <a href="#Fig4" class="usa-link">4</a>D) groups, no differences were observed in IFN-γ levels before, during, or after treatment. In the RT alone (Fig. <a href="#Fig4" class="usa-link">4</a>B), abemaciclib combined with aPD-L1 (Fig. <a href="#Fig4" class="usa-link">4</a>E), abemaciclib combined with RT (Fig. <a href="#Fig4" class="usa-link">4</a>F), and aPD-L1 combined with RT groups (Fig. <a href="#Fig4" class="usa-link">4</a>G), the IFN-γ levels exhibited slight increase during and post-treatment, although these changes did not reach statistical significance. In the triple combination group (Fig. <a href="#Fig4" class="usa-link">4</a>H), circulating IFN-γ levels significantly increased during treatment (<em>P</em> &lt; 0.001) and then decreased post-treatment.</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369063_12929_2025_1173_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2aba/12369063/60e87f6f7361/12929_2025_1173_Fig4_HTML.jpg" loading="lazy" id="MO4" height="379" width="784" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Circulating IFN-γ levels before, during, and after treatment with different combinations of RT, abemaciclib, and anti-PD-L1 antibody (aPD-L1). Blood samples from the 4T1 mouse model were obtained one day before treatment, during treatment (day 8), and after treatment (day 15). IFN-γ levels were measured using enzyme-linked immunosorbent assays. The IFN-γ levels of the (<strong>A</strong>) control, (<strong>B</strong>) RT alone, (<strong>C</strong>) abemaciclib alone, (<strong>D</strong>) aPD-L1 alone, (<strong>E</strong>) abemaciclib combined with aPD-L1, (<strong>F</strong>) abemaciclib combined with RT, (<strong>G</strong>) aPD-L1 combined with RT, and (<strong>H</strong>) abemaciclib combined with aPD-L1 and RT groups are expressed as mean ± standard deviation. The experiments were repeated three times independently. The differences were assessed by an unpaired two-tailed t-test. Significance levels: *<em>P</em> &lt; 0.05; **<em>P</em> &lt; 0.01; ***<em>P</em> &lt; 0.001</p></figcaption></figure></section><section id="Sec19"><h3 class="pmc_sec_title">CDK4/6 inhibitor, RT, and anti-PD-L1 modulate tumor microenvironment by recruiting CD4 + T cells, CD8 + T cells, and M1 type macrophages</h3>
<p id="Par65">Our findings demonstrated that the triple combination of abemaciclib, aPD-L1, and RT enhanced both antitumor effect and circulating IFN-γ levels. To further understand how this treatment combination affects the tumor microenvironment, we evaluated the changes in immune cell populations across different treatment groups. Using the same 4T1 tumor mouse model with the same treatment schedule, we excised tumors right after treatment (Fig. <a href="#Fig5" class="usa-link">5</a>A) to assess TILs, including CD4 + T cells, CD8 + T cells, macrophages, monocytic<em>-</em>myeloid-derived suppressor cells (M-MDSCs)<em>,</em> and regulatory T cells (Tregs) under various treatment conditions. The gating strategies are illustrated in Supplementary Fig. 3.</p>
<figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369063_12929_2025_1173_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2aba/12369063/fa43a3560f5e/12929_2025_1173_Fig5_HTML.jpg" loading="lazy" id="MO5" height="731" width="784" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Tumor-infiltrating lymphocyte (TIL) analysis in tumors excised from an in vivo mouse model receiving treatment with different combinations of abemaciclib, RT, and anti-PD-L1 antibody (aPD-L1). <strong>A</strong> TILs were analyzed from the excised tumors from a 4T1 mouse model subjected to different treatment conditions, including control, RT alone, abemaciclib alone, aPD-L1 alone, abemaciclib combined with aPD-L1, abemaciclib combined with RT, aPD-L1 combined with RT, and abemaciclib combined with aPD-L1 and RT. The tumors were collected after the two-week treatment (on day 15). <strong>B</strong> The CD4 + T cells, <strong>C</strong> CD8 + T cells, <strong>D</strong> regulatory T cells (Tregs), <strong>E</strong> macrophages, and <strong>F</strong> the monocytic-myeloid-derived suppressor cells (M-MDSC) were quantified and displayed as number of cells per gram. The CD8 to Treg ratio is demonstrated (<strong>G</strong>). All data are presented as mean ± standard deviation. The experiments were repeated three times. The differences in TILs in different treatment conditions were assessed by an unpaired two-tailed t-test. Significance levels: *<em>P</em> &lt; 0.05; **<em>P</em> &lt; 0.01; ***<em>P</em> &lt; 0.001; ****<em>P</em> &lt; 0.0001</p></figcaption></figure><p id="Par66">We observed that the triple combination group (abemaciclib combined with aPD-L1 and RT) exhibited significantly increased infiltration of CD4 + T cells compared to the control (<em>P</em> &lt; 0.0001), RT alone (<em>P</em> &lt; 0.001), abemaciclib alone (<em>P</em> &lt; 0.001), aPD-L1 alone (<em>P</em> &lt; 0.001), and abemaciclib combined with aPD-L1 groups (<em>P</em> &lt; 0.0001), as shown in Fig. <a href="#Fig5" class="usa-link">5</a>B. Additionally, CD8 + T cells were significantly increased in the triple combination group compared to all other groups (All <em>P</em> &lt; 0.01), as shown in Fig. <a href="#Fig5" class="usa-link">5</a>C.</p>
<p id="Par67">Macrophage numbers also increased after the triple combination treatment, as depicted in Fig. <a href="#Fig5" class="usa-link">5</a>E. This increase was significant compared to that in the control (<em>P</em> &lt; 0.05), RT alone (<em>P</em> &lt; 0.01), abemaciclib alone (<em>P</em> &lt; 0.05), aPD-L1 alone (<em>P</em> &lt; 0.05), abemaciclib combined with aPD-L1 (<em>P</em> &lt; 0.001), abemaciclib combined with RT (<em>P</em> &lt; 0.01), and aPD-L1 combined with RT (<em>P</em> &lt; 0.01) groups. Conversely, no significant differences were observed in Tregs, M-MDSCs, or the CD8 to Treg ratio among the treatment groups (Fig. <a href="#Fig5" class="usa-link">5</a>D, <a href="#Fig5" class="usa-link">F</a>, and <a href="#Fig5" class="usa-link">G</a>).</p>
<p id="Par68">To confirm the changes in the tumor microenvironment under different treatment conditions, we performed IHC staining on the resected tumors from 4T1 and EMT6 mouse models. We assessed the expression of PD-L1 in tumor cells of murine EMT6 cells (in vivo model) treated with different modalities via IHC analysis. Our findings revealed that PD-L1 expression was significantly upregulated in the tumor cells of the RT alone, abemaciclib with RT, aPD-L1 with RT, and triple combination groups in comparison with the control group (<em>P</em> &lt; 0.05, <em>P</em> &lt; 0.001, <em>P</em> &lt; 0.0001, and <em>P</em> &lt; 0.001, respectively). In contrast, no changes in PD-L1 expression were observed in the abemaciclib, aPD-L1, and abemaciclib plus aPD-L1 groups (Supplementary Fig. 4).</p>
<p id="Par69">In 4T1 mouse model, we found that CD4 + T cell numbers were higher in the triple combination group than in the other five groups, including the control (<em>P</em> &lt; 0.01), RT alone (<em>P</em> &lt; 0.0001), abemaciclib alone (<em>P</em> &lt; 0.001), aPD-L1 alone (<em>P</em> &lt; 0.0001), abemaciclib combined with aPD-L1 (<em>P</em> &lt; 0.0001), abemaciclib combined with RT (<em>P</em> &lt; 0.0001), and aPD-L1 combined with RT (<em>P</em> &lt; 0.01) groups (Fig. <a href="#Fig6" class="usa-link">6</a>A and <a href="#Fig6" class="usa-link">G</a>). In addition, the triple combination group had a significantly higher number of CD8 + T cells than the other five groups (Fig. <a href="#Fig6" class="usa-link">6</a>B and <a href="#Fig6" class="usa-link">H</a>, <em>P</em> &lt; 0.0001 compared to all other groups). Tumor-associated macrophages can exhibit a pro-inflammatory M1 or immunosuppressive M2 phenotype. To distinguish the subtypes of increased macrophages observed in the tumor-infiltrating lymphocytes analysis, we used MCP-1, CD80, and iNOS as M1 markers [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>–<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>], while CD206 as an M2 marker [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>]. We found that the number of MCP-1 positive cells was higher in the triple combination group than in the other five groups (<em>P</em> &lt; 0.0001) as in Fig. <a href="#Fig6" class="usa-link">6</a>C and <a href="#Fig6" class="usa-link">I</a>. Similarly, the number of CD80-positive and iNOS-positive cells was also elevated in the triple combination group compared to the other treatment groups (Fig. <a href="#Fig6" class="usa-link">6</a>D, <a href="#Fig6" class="usa-link">E</a>, <a href="#Fig6" class="usa-link">J</a>, and <a href="#Fig6" class="usa-link">K</a>) (all <em>P</em> &lt; 0.01), further supporting an increase in M1-type macrophages with this treatment. The number of CD206-positive cells, indicative of M2 macrophages, decreased in the triple combination group in comparison with that in the control group (<em>P</em> &lt; 0.0001) (Fig. <a href="#Fig6" class="usa-link">6</a>E and <a href="#Fig6" class="usa-link">J</a>). This shift in macrophage populations, characterized by an increase in pro-inflammatory M1 macrophages (MCP-1 +, CD80 +, and iNOS +) and a decrease in immunosuppressive M2 macrophages (CD206 +), suggests that the triple combination treatment effectively reprogrammed the tumor microenvironment toward an immunostimulatory state. We performed IHC staining and analysis of the EMT6 mouse model and observed consistent results (Supplementary Fig. 5). This further supports the robust effect of triple combination treatment in modulating the tumor microenvironment in different TNBC mouse models.</p>
<figure class="fig xbox font-sm" id="Fig6"><h4 class="obj_head">Fig. 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369063_12929_2025_1173_Fig6_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2aba/12369063/3eba04391f09/12929_2025_1173_Fig6_HTML.jpg" loading="lazy" id="MO6" height="678" width="784" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Immunohistochemical staining of CD4 + T cells, CD8 + T cells, and MCP-1-, CD80-, iNOS- and CD206-positive macrophages in tumors excised from an in vivo model after treatment with different combinations of abemaciclib, RT, and anti-PD-L1 antibody (aPD-L1). Immunohistochemical staining of the resected mouse tumors from 4T1 was performed for CD4, CD8, MCP-1, CD80, and CD206. The upper panel shows (<strong>A</strong>) CD4 + , (<strong>B</strong>) CD8 + , (<strong>C</strong>) MCP-1 + , (<strong>D</strong>) CD80 + , (<strong>E</strong>) iNOS + , and (<strong>F</strong>) CD206 + cells in the different treatment groups, including the control, RT alone, abemaciclib alone, aPD-L1 alone, abemaciclib combined with aPD-L1, abemaciclib combined with RT, aPD-L1 combined with RT, and abemaciclib combined with aPD-L1 and RT groups. The scale bar represents 50 μm. The lower panel shows the quantification of the average number of CD4 + T cells (<strong>G</strong>), CD8 + T cells (<strong>H</strong>), MCP-1 + (<strong>I</strong>), CD80 + (<strong>J</strong>), iNOS + (<strong>K</strong>), and CD206 + (<strong>L</strong>) cells within the resected tumor in the high-power field of the image. The differences were assessed by an unpaired two-tailed t-test. Significance levels: **<em>P</em> &lt; 0.01; ***<em>P</em> &lt; 0.001; ****<em>P</em> &lt; 0.0001</p></figcaption></figure></section></section><section id="Sec20"><h2 class="pmc_sec_title">Discussion</h2>
<p id="Par70">Poor prognosis and lack of specific treatment targets make TNBC treatment difficult. While advancements in molecular diagnostics have led to targeted therapies, such as poly-(ADP-ribose) polymerase (PARP) inhibitors and antibody–drug conjugates [<a href="#CR47" class="usa-link" aria-describedby="CR47">47</a>], these treatments have not significantly impacted clinical practice due to the heterogeneity of TNBC.</p>
<p id="Par71">CDK4/6 inhibitors have demonstrated synergistic effects with anti-estrogen therapies. For example, palbociclib combined with letrozole prolonged survival in ER-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, establishing this combination as a first-line therapy [<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>]. The efficacy of CDK4/6 inhibition depends on the functional RB phosphorylation [<a href="#CR49" class="usa-link" aria-describedby="CR49">49</a>]. As RB is frequently lost in TNBC tumor samples [<a href="#CR50" class="usa-link" aria-describedby="CR50">50</a>], CDK4/6 inhibitors are generally thought to be ineffective against these cancers. However, preclinical studies paint a different picture. Asghar et al. conducted a detailed analysis using a panel of 12 TNBC cell lines, demonstrating that luminal androgen receptor-positive TNBC cells were more responsive to CDK4/6 inhibitors (palbociclib and ribociclib) than basal-like cell lines such as MDA-MB-468 [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>]. In our study, all TNBC cell lines (MDA-MB-231, MDA-MB-453, MDA-MB-468, 4T1, and EMT6) were sensitive to abemaciclib, which is 5.5 times more potent than palbociclib in terms of cell killing efficiency [<a href="#CR51" class="usa-link" aria-describedby="CR51">51</a>].</p>
<p id="Par72">The radiosensitizing effect of CDK4/6 inhibitors has been well-documented [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>, <a href="#CR53" class="usa-link" aria-describedby="CR53">53</a>], primarily by impairing DNA repair mechanisms. DNA damage, particularly double-strand breaks, triggers a complex post-translational network known as the DNA damage response. Previous studies have shown that combining CDK4/6 inhibitors with ionizing radiation delays DNA repair and increases γH2AX levels 24 h post-radiation [<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. Pesch et al. showed that RB expression in tumor cells dictates the response to the CDK4/6 inhibitor palbociclib combined with RT in TNBC [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>]. In this study, the radiosensitizing effect of abemaciclib was demonstrated in three human and two murine TNBC cell lines. All five cell lines expressed RB, and treatment with abemaciclib significantly reduced p-RB levels. These findings are consistent with those reported by Pesch et al., highlighting the critical role of RB in mediating the response to CDK4/6 inhibitors in combination with RT in TNBC [<a href="#CR54" class="usa-link" aria-describedby="CR54">54</a>].</p>
<p id="Par73">CDK4/6 inhibitors have been reported to enhance the immune response in several ways, including promoting cytotoxic T-cell activity, enhancing tumor antigen presentation, and recruiting innate immune cells [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]. Additionally, CDK4/6 inhibitors activate the expression of endogenous retroviral elements in tumor cells, stimulate the production of type III interferons, and further boost antigen presentation in tumors [<a href="#CR55" class="usa-link" aria-describedby="CR55">55</a>]. CDK4/6 inhibitors also significantly limit the abundance of Tregs [<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>], collectively enhancing the immune response and antitumor effects. Building on these mechanistic data, we selected an oral abemaciclib dose of 50 mg/kg once daily for 14 days, combined with two weekly fractions of 8 Gy RT based on robust pre-clinical evidence. Torres-Guzmán et al. showed that 50 mg/kg abemaciclib yields sustained tumor regression [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>], Flint et al. confirmed favorable tissue penetration at similar abemaciclib exposures [<a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>], while Buchwald et al<em>.</em> and Dewan et al<em>.</em> [<a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>, <a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>] demonstrated that hypofractionated RT doses of 8–10 Gy, administered two to three times, optimally prime dendritic cells and synergize with immune checkpoint blockade. Collectively, these findings support the use of a pharmacologically active yet well-tolerated regimen.</p>
<p id="Par74">In a recent clinical trial published by Rugo et al. [<a href="#CR56" class="usa-link" aria-describedby="CR56">56</a>], combining abemaciclib with pembrolizumab showed promising activity but marked grade ≥ 3 toxicities in patients with hormone receptor-positive and HER2-negative metastatic breast cancer. In view of this finding, we purposely used sub-IC₅₀ concentrations (100–200 nM) and the lowest effective murine dose (50 mg/kg QD) of abemaciclib [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>, <a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>, <a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. These attenuated exposures of abemaciclib still sensitized TNBC cells to RT and—when combined with two fractions of 8 Gy RT and aPD-L1—increased tumor control without detectable toxicity. These results suggest that any future clinical trial combining CDK4/6 inhibition with RT and PD-L1 blockade should initiate dose exploration at the lowest feasible abemaciclib level and escalate only as safety permits.</p>
<p id="Par75">Some studies have shown that CDK4/6 inhibitors upregulate PD-L1 expression [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>], suggesting that combining CDK4/6 inhibitors with ICIs could be beneficial. Deng et al. showed that combining ICIs with CDK4/6 inhibitors effectively reduced tumor proliferation in an in vivo model, highlighting the potential of this therapeutic strategy [<a href="#CR43" class="usa-link" aria-describedby="CR43">43</a>]. However, the regulation of PD-L1 by CDK4/6 blockade is highly context-dependent. In this study, abemaciclib did not upregulate PD-L1 expression in any TNBC cell line. The impact of CDK4/6 inhibitors on PD-L1 expression has been inconsistent across studies. Murine 4T1 and EMT6 cells are RB-proficient and exhibit relatively high basal PD-L1, a setting in which recent mechanistic work by Shrestha et al. showed that CDK4/6 inhibition can suppress rather than induce PD-L1 through a phosphorylated RB–E2F1–SPOP axis [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>]. In contrast, PD-L1 upregulation is more frequently observed in ER-positive or RB-deficient models, where transcriptional activation outweighs SPOP-mediated degradation [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>]. Additional variables—such as solvent pH, treatment duration, and glycolytic acidification—can further shift the balance between PD-L1 synthesis and turnover [<a href="#CR58" class="usa-link" aria-describedby="CR58">58</a>]. The interaction between CDK4/6 inhibitors and speckle-type POZ proteins may also contribute to this discrepancy [<a href="#CR57" class="usa-link" aria-describedby="CR57">57</a>].</p>
<p id="Par76">The success of immunotherapy has improved the survival rate of patients with TNBC. However, ICIs alone appear to be less effective than combination therapy. The Keynote 086 trial showed that pembrolizumab benefits only a small proportion of patients with advanced-stage PD-L1-positive TNBC [<a href="#CR59" class="usa-link" aria-describedby="CR59">59</a>]. Similarly, Emens et al<em>.</em> reported a limited effect of the anti-PD-L1 agent, atezolizumab, in patients with metastatic TNBC [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. Studies have indicated that combining immunotherapy with other antitumor agents is more effective than immunotherapy alone [<a href="#CR60" class="usa-link" aria-describedby="CR60">60</a>]. The rationale behind this combination is the potentiation of the immune system by other treatments such as chemotherapy, RT, and targeted therapies. Combining chemotherapy and immunotherapy successfully prolonged overall survival in patients with metastatic TNBC and a PD-L1 combined positive score of 10 or more [<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>]. The combination of pembrolizumab and chemotherapy also benefits patients with early-stage TNBC [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. However, PD-L1 expression is not a reliable predictor of checkpoint inhibitor response, as seen in KEYNOTE-522 [<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>], where PD-L1 status did not predict the pathological complete response rate. Although combination therapy improved survival in the KEYNOTE-355 trial [<a href="#CR61" class="usa-link" aria-describedby="CR61">61</a>], approximately half of the patients with TNBC did not respond to immunotherapy combined with chemotherapy. This suboptimal response rate prompted us to develop new combinations of immunotherapies for treating TNBC. Therefore, the main challenge is to explore new treatment strategies for enhancing the tumor response of TNBC to immunotherapy and reversing the resistance of responders to ICIs.</p>
<p id="Par77">As previously mentioned, CDK4/6 inhibitors and RT have been reported to independently enhance immune responses. Multiple pre-clinical studies have indicated that these three treatments (RT, abemaciclib, and aPD-L1) relieve distinct, non-overlapping bottlenecks in the cancer-immunity cycle. RT supplies tumor antigens and type I IFN/STING signaling but simultaneously induces PD-L1 expression and recruits suppressive myeloid cells, limiting its stand-alone efficacy [<a href="#CR62" class="usa-link" aria-describedby="CR62">62</a>]. CDK4/6 inhibition with abemaciclib augments antigen presentation, upregulates IFN-stimulated genes, and promotes inflammation within the tumor microenvironment, thereby priming CD8⁺ T-cell infiltration; however, this inflammatory response may still be checked by PD-L1 upregulation. Checkpoint blockade removes that brake yet remains ineffective in “cold” tumors unless antigen release and innate priming have already occurred [<a href="#CR52" class="usa-link" aria-describedby="CR52">52</a>]. When all three modalities are combined, the antigen supply (RT), inflammatory conditioning (abemaciclib), and checkpoint relief (aPD-L1) act together, resulting in non-linear tumor control. Our data align with this model: RT + aPD-L1 doublet did not exceed RT alone, showing comparable circulating IFN-γ, CD4⁺/CD8⁺ T-cell density and M1 macrophage levels (Figs. <a href="#Fig4" class="usa-link">4</a>, <a href="#Fig5" class="usa-link">5</a>, <a href="#Fig6" class="usa-link">6</a>). The RT + abemaciclib doublet produced only a modest, non-significant rise in IFN-γ and CD8⁺ T-cell infiltration (Figs. <a href="#Fig4" class="usa-link">4</a>, <a href="#Fig5" class="usa-link">5</a>, <a href="#Fig6" class="usa-link">6</a>), suggesting that residual PD-L1 signaling may still have dampened effector activity. The abemaciclib + aPD-L1 doublet lacked the immunogenic boost provided by RT; therefore, it may not have generated sufficient tumor antigen release to prime a stronger adaptive response, which could explain its limited benefit over monotherapy. Only the triple combination raised IFN-γ and immune-cell infiltration and significantly delayed tumor growth (Figs. <a href="#Fig4" class="usa-link">4</a>, <a href="#Fig5" class="usa-link">5</a>, <a href="#Fig6" class="usa-link">6</a>). A recent independent study reached a similar conclusion: adding abemaciclib converted a partially active RT + aPD-L1 doublet into a markedly effective triplet by further inflaming the tumor microenvironment and enhancing CD8⁺ infiltration [<a href="#CR63" class="usa-link" aria-describedby="CR63">63</a>]. Taken together, these findings explain the apparent non-linearity and underscore the necessity of simultaneously addressing all three immune evasion axes.</p>
<p id="Par78">Our study is the first to combine these two immune-responsive potentiators to improve immunotherapeutic outcomes in TNBC. We used two immunocompetent mouse models in this study: the 4T1 model, which was selected for its poor immunogenicity and high metastatic potential, reflecting the characteristics of advanced human TNBC [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>], and the EMT6 model, which was chosen for its relatively high immunogenicity [<a href="#CR64" class="usa-link" aria-describedby="CR64">64</a>]. Our findings showed that the triple combination of abemaciclib, RT, and aPD-L1 significantly increases circulating IFN-γ levels more than other treatment strategies. IFN-γ is known to stimulate antigen-presenting cells, inhibit the function of MDSCs, and induce a phenotypic switch in tumor-associated macrophages from the M2 to M1 subtype [<a href="#CR46" class="usa-link" aria-describedby="CR46">46</a>]. Although previous studies have indicated that CDK4/6 inhibitors suppress Tregs, this effect was not clearly observed in our study, likely due to the opposing influence of RT [<a href="#CR65" class="usa-link" aria-describedby="CR65">65</a>], which has been reported to increase Treg numbers and recruit them to the tumor site. As shown in Fig. <a href="#Fig5" class="usa-link">5</a>D, RT alone, RT combined with abemaciclib, and RT combined with abemaciclib and aPD-L1 increased Treg numbers, although the differences were not significant. Neither abemaciclib nor RT combined with aPD-L1 increased CD4 + T cells, CD8 + T cells, or tumor-associated macrophages as effectively as the triple combination, as confirmed by IHC staining.</p>
<p id="Par79">Our findings suggest a potential synergy between RT, aPD-L1, and abemaciclib; however, the underlying mechanisms remain only partially understood. RT and PD-L1 blockade alone did not significantly enhance immune cell infiltration, likely due to persistent immunosuppressive factors within the tumor microenvironment. We propose that abemaciclib plays a critical role in overcoming this suppression by promoting T-cell activation and reprogramming macrophage populations toward a pro-inflammatory, immunostimulatory phenotype. Further investigations, including functional and mechanistic studies, are necessary to comprehensively elucidate these interactions.</p>
<p id="Par80">While MCP-1, CD80, and CD206 were used as markers to characterize macrophage phenotypes, these markers have limitations. MCP-1, though associated with M1 macrophages, is context-dependent and linked to pro-tumorigenic roles such as recruiting monocytes that differentiate into M2-like macrophages [<a href="#CR66" class="usa-link" aria-describedby="CR66">66</a>]. CD80 and CD206, which are widely accepted markers for M1 and M2 macrophages, respectively [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>, <a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>, <a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>], provide only a partial view of macrophage functionality. Therefore, we examined iNOS, a well-established functional hallmark of M1 macrophages, and found that its immunohistochemical staining pattern in both 4T1 and EMT6 tumors paralleled the enrichment of CD80 and MCP-1, further corroborating M1-skewed reprogramming in our triple combination (abemaciclib, RT, and aPD-L1)-treated mice [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>, <a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>]. Nevertheless, the binary M1/M2 paradigm is increasingly regarded as an oversimplification because tumor-associated macrophages often display hybrid or transitional phenotypes along a continuum, relying on single markers risks misclassification. Current consensus guidelines therefore advocate multi-parameter validation, integrating additional markers (e.g., major histocompatibility complex class II, arginase 1) [<a href="#CR67" class="usa-link" aria-describedby="CR67">67</a>, <a href="#CR68" class="usa-link" aria-describedby="CR68">68</a>], and functional read-outs together with transcriptomic or metabolic profiling to substantiate macrophage reprogramming.</p>
<p id="Par81">A limitation of this study is that immune activation was evaluated only by serum IFN-γ. Chemokines in the CXCL9/10/11–CXCR3 axis, which are essential for recruiting effector CXCR3<sup>+</sup> T cells and predicting the response to RT and ICI combinations, were not measured here [<a href="#CR69" class="usa-link" aria-describedby="CR69">69</a>, <a href="#CR70" class="usa-link" aria-describedby="CR70">70</a>]. Likewise, tumor necrosis factor (TNF)-α can shape antigen presentation and T-cell function but exhibits context-dependent, bidirectional effects [<a href="#CR71" class="usa-link" aria-describedby="CR71">71</a>]. Future work will therefore include multiplex profiling of CXCL9/10/11, TNF-α, and related mediators to provide a more comprehensive view of treatment-induced immune modulation.</p>
<p id="Par82">The triple combination demonstrated a stronger correlation with increased immune cell infiltration, indicating a potential association with a more immunostimulatory tumor microenvironment (Fig. <a href="#Fig7" class="usa-link">7</a>). This was reflected in the observed reduction in tumor size, wherein the triple combination showed the most substantial tumor growth inhibition among all treatment strategies in 4T1 and EMT6 murine TNBC cell line-derived xenograft immunocompetent mice.</p>
<figure class="fig xbox font-sm" id="Fig7"><h3 class="obj_head">Fig. 7.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12369063_12929_2025_1173_Fig7_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2aba/12369063/b4c77924506b/12929_2025_1173_Fig7_HTML.jpg" loading="lazy" id="MO7" height="319" width="797" alt="Fig. 7"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Modulation of the tumor microenvironment enhances antitumor efficacy in TNBC through triple combination therapy. The combination of CDK4/6 inhibitors, radiotherapy (RT), and anti-PD-L1 immunotherapy demonstrates potential antitumor effects in triple-negative breast cancer (TNBC). This treatment approach is associated with increased levels of circulating IFN-γ, enhanced recruitment of immune cells such as CD4 + and CD8 + T cells, and a shift in macrophage populations towards an immunostimulatory phenotype</p></figcaption></figure></section><section id="Sec21"><h2 class="pmc_sec_title">Conclusions</h2>
<p id="Par83">In the present study, we investigated the synergistic potential of combining CDK4/6 inhibitors, RT, and ICIs to improve the outcomes of TNBC treatment. Using 4T1 and EMT6 murine TNBC cell line-derived immunocompetent mouse models, our study demonstrated that the triple combination of abemaciclib, aPD-L1, and RT significantly reduced tumor growth. The triple combination treatment increased circulating IFN-γ levels and enhanced the recruitment of CD4 + T cells, CD8 + T cells, and M1 macrophages within the tumor microenvironment, potentially contributing to an improved antitumor immune response and tumor growth inhibition. Further exploration of the treatment efficacy of high-dose RT in combination with abemaciclib and ICIs in patients with advanced or metastatic TNBC is warranted.</p></section><section id="Sec22"><h2 class="pmc_sec_title">Ethic approval and consent to participate</h2>
<p id="Par84">The experimental procedures of animal models were approved by the Institutional Animal Care and Use Committee of the National Taiwan University College of Medicine and College of Public Health (IACUC Number 20210366).</p></section><section id="Sec23"><h2 class="pmc_sec_title">Consent for publication</h2>
<p id="Par85">Not applicable.</p></section><section id="Sec24"><h2 class="pmc_sec_title">Competing interests</h2>
<p id="Par86">The authors declare no competing interests.</p></section><section id="Sec25"><h2 class="pmc_sec_title">Supplementary Information</h2>
<section class="sm xbox font-sm" id="MOESM1"><div class="media p"><div class="caption">
<a href="/articles/instance/12369063/bin/12929_2025_1173_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12929_2025_1173_MOESM1_ESM.docx</a><sup> (105.8KB, docx) </sup><p>Additional file 1: Supplementary Fig. 1. The cell survival of MDA-MB-231, MDA-MB-453, and MDA-MB-468 was measured with Cell Proliferation Assay. IC50 values for abemaciclib were found to be 12.15, 2.86, and 8.01 μM for MDA-MB-231, MDA-MB-453, and MDA-MB-468 cells, respectively; and the corresponding cell survival curves were demonstrated. All experiments were performed three times.</p>
</div></div></section><section class="sm xbox font-sm" id="MOESM2"><div class="media p"><div class="caption">
<a href="/articles/instance/12369063/bin/12929_2025_1173_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12929_2025_1173_MOESM2_ESM.docx</a><sup> (235.2KB, docx) </sup><p>Additional file 2: Supplementary Fig. 2. The expression of retinoblastoma (RB) and phosphorylated (p)-RB in five triple-negative breast cancer cell lines treated with different conditions of abemaciclib and radiotherapy (RT) using western blot analysis. All experiments were performed three times. The quantification data are presented with mean ± standard deviation. Significance levels: * <em>P</em> &lt; 0.05; ** <em>P</em> &lt; 0.01; *** <em>P</em> &lt; 0.001; **** <em>P</em> &lt; 0.0001.</p>
</div></div></section><section class="sm xbox font-sm" id="MOESM3"><div class="media p"><div class="caption">
<a href="/articles/instance/12369063/bin/12929_2025_1173_MOESM3_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12929_2025_1173_MOESM3_ESM.docx</a><sup> (16.9MB, docx) </sup><p>Additional file 3: Supplementary Fig. 3. The gating strategy of tumor-infiltrating lymphocytes (TILs) in various treatments, including control, radiotherapy (RT), abemaciclib (Abe), anti-PD-L1 antibody (aPD-L1), Abe combined with aPD-L1, Abe combined with RT, aPD-L1 combined with RT, and the triple combination of Abe with aPD-L1 and RT. The M-MDSC gating strategy is listed separately.</p>
</div></div></section><section class="sm xbox font-sm" id="MOESM4"><div class="media p"><div class="caption">
<a href="/articles/instance/12369063/bin/12929_2025_1173_MOESM4_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12929_2025_1173_MOESM4_ESM.docx</a><sup> (11.5MB, docx) </sup><p>Additional file 4: Supplementary Fig. 4. Immunohistochemical staining of PD-L1 in tumors (EMT6 immunocompetent mouse model) following treatment with abemaciclib, radiotherapy (RT), and anti-PD-L1 antibody (aPD-L1). Tumors excised from treated mice were stained for PD-L1. (A)-(H) display PD-L1 across different treatment groups, including the control, RT alone, abemaciclib alone, aPD-L1 alone, and their combinations. Scale bar: 50 μm. (I) shows the quantification of PD-L1 staining, presented as the average number of cells per high-power field. Statistical significance was assessed using an unpaired two-tailed t-test. Significance levels: *** <em>P</em> &lt; 0.001; **** <em>P</em> &lt; 0.0001.</p>
</div></div></section><section class="sm xbox font-sm" id="MOESM5"><div class="media p"><div class="caption">
<a href="/articles/instance/12369063/bin/12929_2025_1173_MOESM5_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12929_2025_1173_MOESM5_ESM.docx</a><sup> (63.6MB, docx) </sup><p>Additional file 5: Supplementary Fig. 5. Immunohistochemical staining of CD4 + T cells, CD8 + T cells, MCP-1 + , CD80 + , iNOS + , and CD206 + macrophages in tumors (EMT6 immunocompetent mouse model) following treatment with abemaciclib, radiotherapy (RT), and anti-PD-L1 antibody (aPD-L1). Tumors excised from treated mice were stained for CD4, CD8, MCP-1, CD80, iNOS, and CD206. The upper panel displays representative images of (A) CD4 + , (B) CD8 + , (C) MCP-1 + , (D) CD80 + , (E) iNOS + , and (F) CD206 + cells across different treatment groups, including the control, RT alone, abemaciclib alone, aPD-L1 alone, and their combinations. Scale bar: 50 μm. The lower panel quantifies the average number of (G) CD4 + T cells, (H) CD8 + T cells, (I) MCP-1 + cells, (J) CD80 + , (K) iNOS + , and (L) CD206 + cells per high-power field. Statistical significance was assessed using an unpaired two-tailed t-test. Significance levels: * <em>P</em> &lt; 0.05; ** <em>P</em> &lt; 0.01; *** <em>P</em> &lt; 0.001; **** <em>P</em> &lt; 0.0001.</p>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>We thank the staff of the Third Core Lab, Department of Medical Research, National Taiwan University Hospital, for technical support during the study.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>aPD-L1</dt>
<dd><p id="Par5">Anti-programmed death-ligand 1 antibody</p></dd>
<dt>ATCC</dt>
<dd><p id="Par6">American type culture collection</p></dd>
<dt>CDK4/6</dt>
<dd><p id="Par7">Cyclin-dependent kinase 4 and 6</p></dd>
<dt>CI</dt>
<dd><p id="Par8">Combination index</p></dd>
<dt>DMSO</dt>
<dd><p id="Par9">Dimethyl sulfoxide</p></dd>
<dt>DMEM</dt>
<dd><p id="Par10">Dulbecco’s Modified Eagle Medium</p></dd>
<dt>ELISA</dt>
<dd><p id="Par11">Enzyme-linked immunosorbent assay</p></dd>
<dt>ER</dt>
<dd><p id="Par12">Estrogen receptor</p></dd>
<dt>Foxp3</dt>
<dd><p id="Par13">Forkhead box protein P3</p></dd>
<dt>GR-1</dt>
<dd><p id="Par14">Granulocyte receptor-1</p></dd>
<dt>IC50</dt>
<dd><p id="Par15">Half-maximal inhibitory concentration</p></dd>
<dt>HER2</dt>
<dd><p id="Par16"> Human epidermal growth factor receptor 2</p></dd>
<dt>ICI</dt>
<dd><p id="Par17">Immune checkpoint inhibitor</p></dd>
<dt>IFN-γ</dt>
<dd><p id="Par18">Interferon-gamma</p></dd>
<dt>IHC</dt>
<dd><p id="Par19">Immunohistochemistry</p></dd>
<dt>IACUC</dt>
<dd><p id="Par20">Institutional Animal Care and Use Committee</p></dd>
<dt>iNOS</dt>
<dd><p id="Par21">Inducible nitric oxide synthase</p></dd>
<dt>MCP-1</dt>
<dd><p id="Par22">Monocyte chemoattractant protein-1</p></dd>
<dt>MDSC</dt>
<dd><p id="Par23">Myeloid-derived suppressor cell</p></dd>
<dt>M-MDSC</dt>
<dd><p id="Par24">Monocytic myeloid-derived suppressor cell</p></dd>
<dt>PBS</dt>
<dd><p id="Par25">Phosphate-buffered saline</p></dd>
<dt>PD-L1</dt>
<dd><p id="Par26">Programmed death-ligand 1</p></dd>
<dt>PFS</dt>
<dd><p id="Par27">Progression-free survival</p></dd>
<dt>p-RB</dt>
<dd><p id="Par28">Phosphorylated retinoblastoma protein</p></dd>
<dt>RB</dt>
<dd><p id="Par29">Retinoblastoma protein</p></dd>
<dt>RPMI</dt>
<dd><p id="Par30">Roswell Park Memorial Institute medium</p></dd>
<dt>RT</dt>
<dd><p id="Par31">Radiotherapy</p></dd>
<dt>SD</dt>
<dd><p id="Par32">Standard deviation</p></dd>
<dt>TILs</dt>
<dd><p id="Par33">Tumor-infiltrating lymphocytes</p></dd>
<dt>TNF-α</dt>
<dd><p id="Par34">Tumor necrosis factor-α </p></dd>
<dt>TNBC</dt>
<dd><p id="Par35">Triple-negative breast cance</p></dd>
<dt>Treg</dt>
<dd><p id="Par36">Regulatory T cell</p></dd>
<dt>α-tubulin</dt>
<dd><p id="Par37">Alpha tubulin</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Author contributions</h2>
<p>Wen-Chi Yang: Conception and design; acquisition of data; analysis and interpretation of data; writing, review, and/or revision of the manuscript. Ming-Feng Wei: Acquisition of data; analysis and interpretation of data; administrative, technical, or material support. Ying-Chun Shen: Analysis and interpretation of data. Chiun-Sheng Huang: Administrative, technical, or material support; study supervision. Sung-Hsin Kuo: Conception and design; analysis and interpretation of data; writing, review, and/or revision of the manuscript; administrative, technical, or material support; study supervision.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>The study was supported by research Grants 111-2314-B-002-143-, 112-2314-B-002-246-, 112-2314-B-002-097-MY3, and 113-2628-B-002-022-MY3 from the National Science and Technology Council, Taiwan.</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>No datasets were generated or analysed during the current study.</p></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm"><div class="fn p" id="fn1">
<p><strong>Publisher's Note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div></div></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.
</cite> [<a href="https://doi.org/10.1038/35021093" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10963602/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Perou%20CM,%20S%C3%B8rlie%20T,%20Eisen%20MB,%20et%20al.%20Molecular%20portraits%20of%20human%20breast%20tumours.%20Nature.%202000;406:747%E2%80%9352." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012;486:405–9.
</cite> [<a href="https://doi.org/10.1038/nature11154" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4148686/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22722202/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Banerji%20S,%20Cibulskis%20K,%20Rangel-Escareno%20C,%20et%20al.%20Sequence%20analysis%20of%20mutations%20and%20translocations%20across%20breast%20cancer%20subtypes.%20Nature.%202012;486:405%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>Lin PH, Tseng LM, Lee YH, et al. Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders. J Formos Med Assoc. 2022;121:2538–47.
</cite> [<a href="https://doi.org/10.1016/j.jfma.2022.05.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35752529/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lin%20PH,%20Tseng%20LM,%20Lee%20YH,%20et%20al.%20Neoadjuvant%20afatinib%20with%20paclitaxel%20for%20triple-negative%20breast%20cancer%20and%20the%20molecular%20characteristics%20in%20responders%20and%20non-responders.%20J%20Formos%20Med%20Assoc.%202022;121:2538%E2%80%9347." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Bianchini G, De Angelis C, Licata L, et al. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2021. 10.1038/s41571-021-00565-2.
</cite> [<a href="https://doi.org/10.1038/s41571-021-00565-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34754128/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bianchini%20G,%20De%20Angelis%20C,%20Licata%20L,%20et%20al.%20Treatment%20landscape%20of%20triple-negative%20breast%20cancer%20-%20expanded%20options,%20evolving%20needs.%20Nat%20Rev%20Clin%20Oncol.%202021.%2010.1038/s41571-021-00565-2." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Emens LA, Cruz C, Eder JP, et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 2019;5:74–82.
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2018.4224" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6439773/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30242306/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Emens%20LA,%20Cruz%20C,%20Eder%20JP,%20et%20al.%20Long-term%20clinical%20outcomes%20and%20biomarker%20analyses%20of%20atezolizumab%20therapy%20for%20patients%20with%20metastatic%20triple-negative%20breast%20cancer:%20a%20phase%201%20study.%20JAMA%20Oncol.%202019;5:74%E2%80%9382." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17:725–41.
</cite> [<a href="https://doi.org/10.1038/s41571-020-0413-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32760014/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Galluzzi%20L,%20Humeau%20J,%20Buqu%C3%A9%20A,%20et%20al.%20Immunostimulation%20with%20chemotherapy%20in%20the%20era%20of%20immune%20checkpoint%20inhibitors.%20Nat%20Rev%20Clin%20Oncol.%202020;17:725%E2%80%9341." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–21.
</cite> [<a href="https://doi.org/10.1056/NEJMoa1910549" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32101663/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Schmid%20P,%20Cortes%20J,%20Pusztai%20L,%20et%20al.%20Pembrolizumab%20for%20early%20triple-negative%20breast%20cancer.%20N%20Engl%20J%20Med.%202020;382:810%E2%80%9321." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Fassl A, Geng Y, Sicinski P. Cdk4 and cdk6 kinases: from basic science to cancer therapy. Science. 2022;375: eabc1495.
</cite> [<a href="https://doi.org/10.1126/science.abc1495" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9048628/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35025636/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fassl%20A,%20Geng%20Y,%20Sicinski%20P.%20Cdk4%20and%20cdk6%20kinases:%20from%20basic%20science%20to%20cancer%20therapy.%20Science.%202022;375:%20eabc1495." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Landis MW, Pawlyk BS, Li T, et al. Cyclin d1-dependent kinase activity in murine development and mammary tumorigenesis. Cancer Cell. 2006;9:13–22.
</cite> [<a href="https://doi.org/10.1016/j.ccr.2005.12.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16413468/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Landis%20MW,%20Pawlyk%20BS,%20Li%20T,%20et%20al.%20Cyclin%20d1-dependent%20kinase%20activity%20in%20murine%20development%20and%20mammary%20tumorigenesis.%20Cancer%20Cell.%202006;9:13%E2%80%9322." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Reddy HK, Mettus RV, Rane SG, et al. Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res. 2005;65:10174–8.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-05-2639" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16288002/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Reddy%20HK,%20Mettus%20RV,%20Rane%20SG,%20et%20al.%20Cyclin-dependent%20kinase%204%20expression%20is%20essential%20for%20neu-induced%20breast%20tumorigenesis.%20Cancer%20Res.%202005;65:10174%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Bartkova J, Lukas J, Müller H, et al. Cyclin D1 protein expression and function in human breast cancer. Int J Cancer. 1994;57:353–61.
</cite> [<a href="https://doi.org/10.1002/ijc.2910570311" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8168995/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bartkova%20J,%20Lukas%20J,%20M%C3%BCller%20H,%20et%20al.%20Cyclin%20D1%20protein%20expression%20and%20function%20in%20human%20breast%20cancer.%20Int%20J%20Cancer.%201994;57:353%E2%80%9361." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Chen F, Zhang Z, Yu Y, et al. Hsulf-1 and palbociclib exert synergistic antitumor effects on rb-positive triple-negative breast cancer. Int J Oncol. 2020;57:223–36.
</cite> [<a href="https://doi.org/10.3892/ijo.2020.5057" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7252455/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32377705/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chen%20F,%20Zhang%20Z,%20Yu%20Y,%20et%20al.%20Hsulf-1%20and%20palbociclib%20exert%20synergistic%20antitumor%20effects%20on%20rb-positive%20triple-negative%20breast%20cancer.%20Int%20J%20Oncol.%202020;57:223%E2%80%9336." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Asghar US, Barr AR, Cutts R, et al. Single-cell dynamics determines response to cdk4/6 inhibition in triple-negative breast cancer. Clin Cancer Res. 2017;23:5561–72.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-17-0369" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6175044/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28606920/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Asghar%20US,%20Barr%20AR,%20Cutts%20R,%20et%20al.%20Single-cell%20dynamics%20determines%20response%20to%20cdk4/6%20inhibition%20in%20triple-negative%20breast%20cancer.%20Clin%20Cancer%20Res.%202017;23:5561%E2%80%9372." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Rao SS, Stoehr J, Dokic D, et al. Synergistic effect of eribulin and cdk inhibition for the treatment of triple negative breast cancer. Oncotarget. 2017;8:83925–39.
</cite> [<a href="https://doi.org/10.18632/oncotarget.20202" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5663565/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29137393/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rao%20SS,%20Stoehr%20J,%20Dokic%20D,%20et%20al.%20Synergistic%20effect%20of%20eribulin%20and%20cdk%20inhibition%20for%20the%20treatment%20of%20triple%20negative%20breast%20cancer.%20Oncotarget.%202017;8:83925%E2%80%9339." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Tan AR, Wright GS, Thummala AR, et al. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2019;20:1587–601.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(19)30616-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31575503/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tan%20AR,%20Wright%20GS,%20Thummala%20AR,%20et%20al.%20Trilaciclib%20plus%20chemotherapy%20versus%20chemotherapy%20alone%20in%20patients%20with%20metastatic%20triple-negative%20breast%20cancer:%20a%20multicentre,%20randomised,%20open-label,%20phase%202%20trial.%20Lancet%20Oncol.%202019;20:1587%E2%80%93601." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Malumbres M, Sotillo R, Santamaría D, et al. Mammalian cells cycle without the d-type cyclin-dependent kinases CDK4 and CDK6. Cell. 2004;118:493–504.
</cite> [<a href="https://doi.org/10.1016/j.cell.2004.08.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15315761/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Malumbres%20M,%20Sotillo%20R,%20Santamar%C3%ADa%20D,%20et%20al.%20Mammalian%20cells%20cycle%20without%20the%20d-type%20cyclin-dependent%20kinases%20CDK4%20and%20CDK6.%20Cell.%202004;118:493%E2%80%93504." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Hurvitz SA, Martin M, Press MF, et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neomonarch, phase II neoadjuvant study in hr(+)/her2(-) breast cancer. Clin Cancer Res. 2020;26:566–80.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-19-1425" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7498177/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31615937/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hurvitz%20SA,%20Martin%20M,%20Press%20MF,%20et%20al.%20Potent%20cell-cycle%20inhibition%20and%20upregulation%20of%20immune%20response%20with%20abemaciclib%20and%20anastrozole%20in%20neomonarch,%20phase%20II%20neoadjuvant%20study%20in%20hr(+)/her2(-)%20breast%20cancer.%20Clin%20Cancer%20Res.%202020;26:566%E2%80%9380." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011;378:1707–16.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(11)61629-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3254252/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22019144/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Darby%20S,%20McGale%20P,%20Correa%20C,%20et%20al.%20Effect%20of%20radiotherapy%20after%20breast-conserving%20surgery%20on%2010-year%20recurrence%20and%2015-year%20breast%20cancer%20death:%20Meta-analysis%20of%20individual%20patient%20data%20for%2010,801%20women%20in%2017%20randomised%20trials.%20Lancet.%202011;378:1707%E2%80%9316." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Sharabi AB, Lim M, DeWeese TL, et al. Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy. Lancet Oncol. 2015;16:e498-509.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(15)00007-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26433823/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sharabi%20AB,%20Lim%20M,%20DeWeese%20TL,%20et%20al.%20Radiation%20and%20checkpoint%20blockade%20immunotherapy:%20Radiosensitisation%20and%20potential%20mechanisms%20of%20synergy.%20Lancet%20Oncol.%202015;16:e498-509." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Ho AY, Barker CA, Arnold BB, et al. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. Cancer. 2020;126:850–60.
</cite> [<a href="https://doi.org/10.1002/cncr.32599" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31747077/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ho%20AY,%20Barker%20CA,%20Arnold%20BB,%20et%20al.%20A%20phase%202%20clinical%20trial%20assessing%20the%20efficacy%20and%20safety%20of%20pembrolizumab%20and%20radiotherapy%20in%20patients%20with%20metastatic%20triple-negative%20breast%20cancer.%20Cancer.%202020;126:850%E2%80%9360." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Hashizume R, Zhang A, Mueller S, et al. Inhibition of DNA damage repair by the cdk4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth. Neuro Oncol. 2016;18:1519–28.
</cite> [<a href="https://doi.org/10.1093/neuonc/now106" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5063519/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27370397/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hashizume%20R,%20Zhang%20A,%20Mueller%20S,%20et%20al.%20Inhibition%20of%20DNA%20damage%20repair%20by%20the%20cdk4/6%20inhibitor%20palbociclib%20delays%20irradiated%20intracranial%20atypical%20teratoid%20rhabdoid%20tumor%20and%20glioblastoma%20xenograft%20regrowth.%20Neuro%20Oncol.%202016;18:1519%E2%80%9328." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Naz S, Sowers A, Choudhuri R, et al. Abemaciclib, a selective cdk4/6 inhibitor, enhances the radiosensitivity of non-small cell lung cancer <em>in vitro</em> and <em>in vivo</em>. Clin Cancer Res. 2018;24:3994–4005.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-17-3575" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6137329/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29716919/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Naz%20S,%20Sowers%20A,%20Choudhuri%20R,%20et%20al.%20Abemaciclib,%20a%20selective%20cdk4/6%20inhibitor,%20enhances%20the%20radiosensitivity%20of%20non-small%20cell%20lung%20cancer%20in%20vitro%20and%20in%20vivo.%20Clin%20Cancer%20Res.%202018;24:3994%E2%80%934005." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase ii keynote-086 study. Ann Oncol. 2019;30:397–404.
</cite> [<a href="https://doi.org/10.1093/annonc/mdy517" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30475950/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Adams%20S,%20Schmid%20P,%20Rugo%20HS,%20et%20al.%20Pembrolizumab%20monotherapy%20for%20previously%20treated%20metastatic%20triple-negative%20breast%20cancer:%20cohort%20a%20of%20the%20phase%20ii%20keynote-086%20study.%20Ann%20Oncol.%202019;30:397%E2%80%93404." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class ii and b7.1 cell-based tumor vaccines. Cancer Res. 1998;58:1486–93.
</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/9537252/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pulaski%20BA,%20Ostrand-Rosenberg%20S.%20Reduction%20of%20established%20spontaneous%20mammary%20carcinoma%20metastases%20following%20immunotherapy%20with%20major%20histocompatibility%20complex%20class%20ii%20and%20b7.1%20cell-based%20tumor%20vaccines.%20Cancer%20Res.%201998;58:1486%E2%80%9393." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Kim K, Skora AD, Li Z, et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. Proc Natl Acad Sci U S A. 2014;111:11774–9.
</cite> [<a href="https://doi.org/10.1073/pnas.1410626111" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4136565/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25071169/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kim%20K,%20Skora%20AD,%20Li%20Z,%20et%20al.%20Eradication%20of%20metastatic%20mouse%20cancers%20resistant%20to%20immune%20checkpoint%20blockade%20by%20suppression%20of%20myeloid-derived%20cells.%20Proc%20Natl%20Acad%20Sci%20U%20S%20A.%202014;111:11774%E2%80%939." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Taylor BC, Sun X, Gonzalez-Ericsson PI, et al. Nkg2a is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple-negative breast cancer. Cancer Discov. 2024;14:290–307.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-23-0519" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10850946/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37791898/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Taylor%20BC,%20Sun%20X,%20Gonzalez-Ericsson%20PI,%20et%20al.%20Nkg2a%20is%20a%20therapeutic%20vulnerability%20in%20immunotherapy%20resistant%20MHC-I%20heterogeneous%20triple-negative%20breast%20cancer.%20Cancer%20Discov.%202024;14:290%E2%80%93307." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Bernhardt T, Kriesen S, Manda K, et al. Induction of radiodermatitis in nude mouse model using gamma irradiator IBL 637. Skin Pharmacol Physiol. 2022;35:224–34.
</cite> [<a href="https://doi.org/10.1159/000524596" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9254314/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35417908/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bernhardt%20T,%20Kriesen%20S,%20Manda%20K,%20et%20al.%20Induction%20of%20radiodermatitis%20in%20nude%20mouse%20model%20using%20gamma%20irradiator%20IBL%20637.%20Skin%20Pharmacol%20Physiol.%202022;35:224%E2%80%9334." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Chou TC. Drug combination studies and their synergy quantification using the chou-talalay method. Cancer Res. 2010;70:440–6.
</cite> [<a href="https://doi.org/10.1158/0008-5472.CAN-09-1947" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20068163/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Chou%20TC.%20Drug%20combination%20studies%20and%20their%20synergy%20quantification%20using%20the%20chou-talalay%20method.%20Cancer%20Res.%202010;70:440%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Buchwald ZS, Wynne J, Nasti TH, et al. Radiation, immune checkpoint blockade and the abscopal effect: a critical review on timing, dose and fractionation. Front Oncol. 2018;8:612.
</cite> [<a href="https://doi.org/10.3389/fonc.2018.00612" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6306034/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30619752/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Buchwald%20ZS,%20Wynne%20J,%20Nasti%20TH,%20et%20al.%20Radiation,%20immune%20checkpoint%20blockade%20and%20the%20abscopal%20effect:%20a%20critical%20review%20on%20timing,%20dose%20and%20fractionation.%20Front%20Oncol.%202018;8:612." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Dewan MZ, Galloway AE, Kawashima N, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15:5379–88.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-09-0265" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2746048/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19706802/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Dewan%20MZ,%20Galloway%20AE,%20Kawashima%20N,%20et%20al.%20Fractionated%20but%20not%20single-dose%20radiotherapy%20induces%20an%20immune-mediated%20abscopal%20effect%20when%20combined%20with%20anti-CTLA-4%20antibody.%20Clin%20Cancer%20Res.%202009;15:5379%E2%80%9388." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Schaer DA, Beckmann RP, Dempsey JA, et al. The cdk4/6 inhibitor abemaciclib induces a t cell inflamed tumor microenvironment and enhances the efficacy of pd-l1 checkpoint blockade. Cell Rep. 2018;22:2978–94.
</cite> [<a href="https://doi.org/10.1016/j.celrep.2018.02.053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29539425/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Schaer%20DA,%20Beckmann%20RP,%20Dempsey%20JA,%20et%20al.%20The%20cdk4/6%20inhibitor%20abemaciclib%20induces%20a%20t%20cell%20inflamed%20tumor%20microenvironment%20and%20enhances%20the%20efficacy%20of%20pd-l1%20checkpoint%20blockade.%20Cell%20Rep.%202018;22:2978%E2%80%9394." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Torres-Guzmán R, Calsina B, Hermoso A, et al. Preclinical characterization of abemaciclib in hormone receptor-positive breast cancer. Oncotarget. 2017;8:69493–507.
</cite> [<a href="https://doi.org/10.18632/oncotarget.17778" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5642494/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29050219/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Torres-Guzm%C3%A1n%20R,%20Calsina%20B,%20Hermoso%20A,%20et%20al.%20Preclinical%20characterization%20of%20abemaciclib%20in%20hormone%20receptor-positive%20breast%20cancer.%20Oncotarget.%202017;8:69493%E2%80%93507." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Flint AC, Mitchell DK, Angus SP, et al. Combined CDK4/6 and ERK1/2 inhibition enhances antitumor activity in NF1-associated plexiform neurofibroma. Clin Cancer Res. 2023;29:3438–56.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-22-2854" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11060649/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37406085/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Flint%20AC,%20Mitchell%20DK,%20Angus%20SP,%20et%20al.%20Combined%20CDK4/6%20and%20ERK1/2%20inhibition%20enhances%20antitumor%20activity%20in%20NF1-associated%20plexiform%20neurofibroma.%20Clin%20Cancer%20Res.%202023;29:3438%E2%80%9356." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3:1355–63.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-13-0310" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3864135/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24078774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Akbay%20EA,%20Koyama%20S,%20Carretero%20J,%20et%20al.%20Activation%20of%20the%20PD-1%20pathway%20contributes%20to%20immune%20escape%20in%20EGFR-driven%20lung%20tumors.%20Cancer%20Discov.%202013;3:1355%E2%80%9363." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Yang WC, Wei MF, Lee YH, et al. Radiosensitizing effects of cdk4/6 inhibitors in hormone receptor-positive and her2-negative breast cancer mediated downregulation of DNA repair mechanism and nf-κb-signaling pathway. Transl Oncol. 2024;49: 102092.
</cite> [<a href="https://doi.org/10.1016/j.tranon.2024.102092" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11381799/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39153367/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20WC,%20Wei%20MF,%20Lee%20YH,%20et%20al.%20Radiosensitizing%20effects%20of%20cdk4/6%20inhibitors%20in%20hormone%20receptor-positive%20and%20her2-negative%20breast%20cancer%20mediated%20downregulation%20of%20DNA%20repair%20mechanism%20and%20nf-%CE%BAb-signaling%20pathway.%20Transl%20Oncol.%202024;49:%20102092." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Kuo SH, Wei MF, Lee YH, et al. Map3k1 expression is associated with progression and poor prognosis of hormone receptor-positive, Her2-negative early-stage breast cancer. Cell Oncol (Dordr). 2023;46:1213–34.
</cite> [<a href="https://doi.org/10.1007/s13402-023-00805-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37166744/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kuo%20SH,%20Wei%20MF,%20Lee%20YH,%20et%20al.%20Map3k1%20expression%20is%20associated%20with%20progression%20and%20poor%20prognosis%20of%20hormone%20receptor-positive,%20Her2-negative%20early-stage%20breast%20cancer.%20Cell%20Oncol%20(Dordr).%202023;46:1213%E2%80%9334." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Takada Y, Hisamatsu T, Kamada N, et al. Monocyte chemoattractant protein-1 contributes to gut homeostasis and intestinal inflammation by composition of IL-10-producing regulatory macrophage subset. J Immunol. 2010;184:2671–6.
</cite> [<a href="https://doi.org/10.4049/jimmunol.0804012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20107182/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Takada%20Y,%20Hisamatsu%20T,%20Kamada%20N,%20et%20al.%20Monocyte%20chemoattractant%20protein-1%20contributes%20to%20gut%20homeostasis%20and%20intestinal%20inflammation%20by%20composition%20of%20IL-10-producing%20regulatory%20macrophage%20subset.%20J%20Immunol.%202010;184:2671%E2%80%936." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>Li W, Katz BP, Spinola SM. <em>Haemophilus ducreyi</em>-induced interleukin-10 promotes a mixed M1 and M2 activation program in human macrophages. Infect Immun. 2012;80:4426–34.
</cite> [<a href="https://doi.org/10.1128/IAI.00912-12" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3497422/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23027536/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Li%20W,%20Katz%20BP,%20Spinola%20SM.%20Haemophilus%20ducreyi-induced%20interleukin-10%20promotes%20a%20mixed%20M1%20and%20M2%20activation%20program%20in%20human%20macrophages.%20Infect%20Immun.%202012;80:4426%E2%80%9334." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Gao X, Usami N, Bandyopadhyay A, et al. Infiltration of polarized macrophages in human breast cancer and their clinical significance. Nat Commun. 2015;6:6676.25813085
</cite> [<a href="https://scholar.google.com/scholar_lookup?Gao%20X,%20Usami%20N,%20Bandyopadhyay%20A,%20et%20al.%20Infiltration%20of%20polarized%20macrophages%20in%20human%20breast%20cancer%20and%20their%20clinical%20significance.%20Nat%20Commun.%202015;6:6676.25813085" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Xu ZJ, Gu Y, Wang CZ, et al. The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia. Oncoimmunology. 2020;9:1683347.
</cite> [<a href="https://doi.org/10.1080/2162402X.2019.1683347" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6959428/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32002295/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xu%20ZJ,%20Gu%20Y,%20Wang%20CZ,%20et%20al.%20The%20M2%20macrophage%20marker%20CD206:%20a%20novel%20prognostic%20indicator%20for%20acute%20myeloid%20leukemia.%20Oncoimmunology.%202020;9:1683347." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Gao X, Leone GW, Wang H. Cyclin d-cdk4/6 functions in cancer. Adv Cancer Res. 2020;148:147–69.
</cite> [<a href="https://doi.org/10.1016/bs.acr.2020.02.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32723562/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gao%20X,%20Leone%20GW,%20Wang%20H.%20Cyclin%20d-cdk4/6%20functions%20in%20cancer.%20Adv%20Cancer%20Res.%202020;148:147%E2%80%9369." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Pesch AM, Hirsh NH, Chandler BC, et al. Short-term CDK4/6 inhibition radiosensitizes estrogen receptor-positive breast cancers. Clin Cancer Res. 2020;26:6568–80.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-20-2269" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7744368/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32967938/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Pesch%20AM,%20Hirsh%20NH,%20Chandler%20BC,%20et%20al.%20Short-term%20CDK4/6%20inhibition%20radiosensitizes%20estrogen%20receptor-positive%20breast%20cancers.%20Clin%20Cancer%20Res.%202020;26:6568%E2%80%9380." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Deng J, Wang ES, Jenkins RW, et al. Cdk4/6 inhibition augments antitumor immunity by enhancing t-cell activation. Cancer Discov. 2018;8:216–33.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-17-0915" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5809273/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29101163/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Deng%20J,%20Wang%20ES,%20Jenkins%20RW,%20et%20al.%20Cdk4/6%20inhibition%20augments%20antitumor%20immunity%20by%20enhancing%20t-cell%20activation.%20Cancer%20Discov.%202018;8:216%E2%80%9333." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Goel S, DeCristo MJ, Watt AC, et al. Cdk4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471–5.
</cite> [<a href="https://doi.org/10.1038/nature23465" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5570667/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28813415/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Goel%20S,%20DeCristo%20MJ,%20Watt%20AC,%20et%20al.%20Cdk4/6%20inhibition%20triggers%20anti-tumour%20immunity.%20Nature.%202017;548:471%E2%80%935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Tang C, Wang X, Soh H, et al. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014;2:831–8.
</cite> [<a href="https://doi.org/10.1158/2326-6066.CIR-14-0069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5367158/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25187273/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tang%20C,%20Wang%20X,%20Soh%20H,%20et%20al.%20Combining%20radiation%20and%20immunotherapy:%20a%20new%20systemic%20therapy%20for%20solid%20tumors?%20Cancer%20Immunol%20Res.%202014;2:831%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Ni L, Lu J. Interferon gamma in cancer immunotherapy. Cancer Med. 2018;7:4509–16.
</cite> [<a href="https://doi.org/10.1002/cam4.1700" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6143921/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30039553/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ni%20L,%20Lu%20J.%20Interferon%20gamma%20in%20cancer%20immunotherapy.%20Cancer%20Med.%202018;7:4509%E2%80%9316." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327–44.
</cite> [<a href="https://doi.org/10.1038/s41571-021-00470-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8287784/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33558752/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Drago%20JZ,%20Modi%20S,%20Chandarlapaty%20S.%20Unlocking%20the%20potential%20of%20antibody-drug%20conjugates%20for%20cancer%20therapy.%20Nat%20Rev%20Clin%20Oncol.%202021;18:327%E2%80%9344." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Cottu P, D’Hondt V, Dureau S, et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer. Ann Oncol. 2018;29:2334–40.
</cite> [<a href="https://doi.org/10.1093/annonc/mdy448" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30307466/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cottu%20P,%20D%E2%80%99Hondt%20V,%20Dureau%20S,%20et%20al.%20Letrozole%20and%20palbociclib%20versus%20chemotherapy%20as%20neoadjuvant%20therapy%20of%20high-risk%20luminal%20breast%20cancer.%20Ann%20Oncol.%202018;29:2334%E2%80%9340." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR49">
<span class="label">49.</span><cite>Guarducci C, Bonechi M, Boccalini G, et al. Mechanisms of resistance to cdk4/6 inhibitors in breast cancer and potential biomarkers of response. Breast Care. 2017;12:304–8.
</cite> [<a href="https://doi.org/10.1159/000484167" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5704709/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29234249/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Guarducci%20C,%20Bonechi%20M,%20Boccalini%20G,%20et%20al.%20Mechanisms%20of%20resistance%20to%20cdk4/6%20inhibitors%20in%20breast%20cancer%20and%20potential%20biomarkers%20of%20response.%20Breast%20Care.%202017;12:304%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR50">
<span class="label">50.</span><cite>Robinson TJ, Liu JC, Vizeacoumar F, et al. Rb1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS ONE. 2013;8: e78641.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0078641" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3827056/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24265703/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Robinson%20TJ,%20Liu%20JC,%20Vizeacoumar%20F,%20et%20al.%20Rb1%20status%20in%20triple%20negative%20breast%20cancer%20cells%20dictates%20response%20to%20radiation%20treatment%20and%20selective%20therapeutic%20drugs.%20PLoS%20ONE.%202013;8:%20e78641." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR51">
<span class="label">51.</span><cite>George MA, Qureshi S, Omene C, et al. Clinical and pharmacologic differences of CDK4/6 inhibitors in breast cancer. Front Oncol. 2021;11: 693104.
</cite> [<a href="https://doi.org/10.3389/fonc.2021.693104" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8313476/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34327137/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?George%20MA,%20Qureshi%20S,%20Omene%20C,%20et%20al.%20Clinical%20and%20pharmacologic%20differences%20of%20CDK4/6%20inhibitors%20in%20breast%20cancer.%20Front%20Oncol.%202021;11:%20693104." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR52">
<span class="label">52.</span><cite>Yang Y, Luo J, Chen X, et al. Cdk4/6 inhibitors: a novel strategy for tumor radiosensitization. J Exp Clin Cancer Res. 2020;39:188.
</cite> [<a href="https://doi.org/10.1186/s13046-020-01693-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7490904/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32933570/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yang%20Y,%20Luo%20J,%20Chen%20X,%20et%20al.%20Cdk4/6%20inhibitors:%20a%20novel%20strategy%20for%20tumor%20radiosensitization.%20J%20Exp%20Clin%20Cancer%20Res.%202020;39:188." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR53">
<span class="label">53.</span><cite>Xie X, Zheng W, Chen T, et al. CDK4/6 inhibitor palbociclib amplifies the radiosensitivity to nasopharyngeal carcinoma cells via mediating apoptosis and suppressing DNA damage repair. Onco Targets Ther. 2019;12:11107–17.
</cite> [<a href="https://doi.org/10.2147/OTT.S234221" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6924590/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31908479/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xie%20X,%20Zheng%20W,%20Chen%20T,%20et%20al.%20CDK4/6%20inhibitor%20palbociclib%20amplifies%20the%20radiosensitivity%20to%20nasopharyngeal%20carcinoma%20cells%20via%20mediating%20apoptosis%20and%20suppressing%20DNA%20damage%20repair.%20Onco%20Targets%20Ther.%202019;12:11107%E2%80%9317." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR54">
<span class="label">54.</span><cite>Pesch AM, Hirsh NH, Michmerhuizen AR, et al. Rb expression confers sensitivity to cdk4/6 inhibitor-mediated radiosensitization across breast cancer subtypes. JCI Insight 2022;7.</cite> [<a href="https://doi.org/10.1172/jci.insight.154402" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8855810/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34932500/" class="usa-link">PubMed</a>]</li>
<li id="CR55">
<span class="label">55.</span><cite>Burton DGA, Stolzing A. Cellular senescence: immunosurveillance and future immunotherapy. Ageing Res Rev. 2018;43:17–25.
</cite> [<a href="https://doi.org/10.1016/j.arr.2018.02.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29427795/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Burton%20DGA,%20Stolzing%20A.%20Cellular%20senescence:%20immunosurveillance%20and%20future%20immunotherapy.%20Ageing%20Res%20Rev.%202018;43:17%E2%80%9325." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR56">
<span class="label">56.</span><cite>Rugo HS, Kabos P, Beck JT, et al. Abemaciclib in combination with pembrolizumab for HR-positive, HER2-negative metastatic breast cancer: phase 1b study. NPJ Breast Cancer. 2022;8:118.
</cite> [<a href="https://doi.org/10.1038/s41523-022-00482-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9637121/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36335120/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rugo%20HS,%20Kabos%20P,%20Beck%20JT,%20et%20al.%20Abemaciclib%20in%20combination%20with%20pembrolizumab%20for%20HR-positive,%20HER2-negative%20metastatic%20breast%20cancer:%20phase%201b%20study.%20NPJ%20Breast%20Cancer.%202022;8:118." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR57">
<span class="label">57.</span><cite>Zhang J, Bu X, Wang H, et al. Cyclin d-cdk4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature. 2018;553:91–5.
</cite> [<a href="https://doi.org/10.1038/nature25015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5754234/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29160310/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20J,%20Bu%20X,%20Wang%20H,%20et%20al.%20Cyclin%20d-cdk4%20kinase%20destabilizes%20PD-L1%20via%20cullin%203-SPOP%20to%20control%20cancer%20immune%20surveillance.%20Nature.%202018;553:91%E2%80%935." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR58">
<span class="label">58.</span><cite>Shrestha M, Wang DY, Ben-David Y, et al. Cdk4/6 inhibitors and the prb-e2f1 axis suppress pvr and pd-l1 expression in triple-negative breast cancer. Oncogenesis. 2023;12:29.
</cite> [<a href="https://doi.org/10.1038/s41389-023-00475-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10213015/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37230983/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Shrestha%20M,%20Wang%20DY,%20Ben-David%20Y,%20et%20al.%20Cdk4/6%20inhibitors%20and%20the%20prb-e2f1%20axis%20suppress%20pvr%20and%20pd-l1%20expression%20in%20triple-negative%20breast%20cancer.%20Oncogenesis.%202023;12:29." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR59">
<span class="label">59.</span><cite>Adams S, Loi S, Toppmeyer D, et al. Pembrolizumab monotherapy for previously untreated, pd-l1-positive, metastatic triple-negative breast cancer: cohort B of the phase II keynote-086 study. Ann Oncol. 2019;30:405–11.
</cite> [<a href="https://doi.org/10.1093/annonc/mdy518" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30475947/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Adams%20S,%20Loi%20S,%20Toppmeyer%20D,%20et%20al.%20Pembrolizumab%20monotherapy%20for%20previously%20untreated,%20pd-l1-positive,%20metastatic%20triple-negative%20breast%20cancer:%20cohort%20B%20of%20the%20phase%20II%20keynote-086%20study.%20Ann%20Oncol.%202019;30:405%E2%80%9311." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR60">
<span class="label">60.</span><cite>Zhu S, Zhang T, Zheng L, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14:156.
</cite> [<a href="https://doi.org/10.1186/s13045-021-01164-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8475356/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34579759/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhu%20S,%20Zhang%20T,%20Zheng%20L,%20et%20al.%20Combination%20strategies%20to%20maximize%20the%20benefits%20of%20cancer%20immunotherapy.%20J%20Hematol%20Oncol.%202021;14:156." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR61">
<span class="label">61.</span><cite>Cortes J, Rugo HS, Cescon DW, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217–26.
</cite> [<a href="https://doi.org/10.1056/NEJMoa2202809" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35857659/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Cortes%20J,%20Rugo%20HS,%20Cescon%20DW,%20et%20al.%20Pembrolizumab%20plus%20chemotherapy%20in%20advanced%20triple-negative%20breast%20cancer.%20N%20Engl%20J%20Med.%202022;387:217%E2%80%9326." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR62">
<span class="label">62.</span><cite>Wang NH, Lei Z, Yang HN, et al. Radiation-induced PD-L1 expression in tumor and its clinical implications. Ann Transl Med. 2022;10:1406.
</cite> [<a href="https://doi.org/10.21037/atm-22-6049" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9843429/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36660640/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20NH,%20Lei%20Z,%20Yang%20HN,%20et%20al.%20Radiation-induced%20PD-L1%20expression%20in%20tumor%20and%20its%20clinical%20implications.%20Ann%20Transl%20Med.%202022;10:1406." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR63">
<span class="label">63.</span><cite>Wang L, Wu Y, Kang K, et al. CDK4/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment. Transl Lung Cancer Res. 2024;13:1032–46.
</cite> [<a href="https://doi.org/10.21037/tlcr-24-33" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11157372/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38854937/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Wang%20L,%20Wu%20Y,%20Kang%20K,%20et%20al.%20CDK4/6%20inhibitor%20abemaciclib%20combined%20with%20low-dose%20radiotherapy%20enhances%20the%20anti-tumor%20immune%20response%20to%20PD-1%20blockade%20by%20inflaming%20the%20tumor%20microenvironment.%20Transl%20Lung%20Cancer%20Res.%202024;13:1032%E2%80%9346." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR64">
<span class="label">64.</span><cite>Gorczynski RM, Chen Z, Erin N, et al. Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy. PLoS ONE. 2014;9: e113597.
</cite> [<a href="https://doi.org/10.1371/journal.pone.0113597" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4237434/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25409195/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gorczynski%20RM,%20Chen%20Z,%20Erin%20N,%20et%20al.%20Comparison%20of%20immunity%20in%20mice%20cured%20of%20primary/metastatic%20growth%20of%20EMT6%20or%204THM%20breast%20cancer%20by%20chemotherapy%20or%20immunotherapy.%20PLoS%20ONE.%202014;9:%20e113597." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR65">
<span class="label">65.</span><cite>Muroyama Y, Nirschl TR, Kochel CM, et al. Stereotactic radiotherapy increases functionally suppressive regulatory t cells in the tumor microenvironment. Cancer Immunol Res. 2017;5:992–1004.
</cite> [<a href="https://doi.org/10.1158/2326-6066.CIR-17-0040" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5793220/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28970196/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Muroyama%20Y,%20Nirschl%20TR,%20Kochel%20CM,%20et%20al.%20Stereotactic%20radiotherapy%20increases%20functionally%20suppressive%20regulatory%20t%20cells%20in%20the%20tumor%20microenvironment.%20Cancer%20Immunol%20Res.%202017;5:992%E2%80%931004." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR66">
<span class="label">66.</span><cite>Yoshimura T. The chemokine mcp-1 (ccl2) in the host interaction with cancer: a foe or ally? Cell Mol Immunol. 2018;15:335–45.
</cite> [<a href="https://doi.org/10.1038/cmi.2017.135" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6052833/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29375123/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Yoshimura%20T.%20The%20chemokine%20mcp-1%20(ccl2)%20in%20the%20host%20interaction%20with%20cancer:%20a%20foe%20or%20ally?%20Cell%20Mol%20Immunol.%202018;15:335%E2%80%9345." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR67">
<span class="label">67.</span><cite>Mei M, Tang L, Zhou H, et al. Honokiol prevents lung metastasis of triple-negative breast cancer by regulating polarization and recruitment of macrophages. Eur J Pharmacol. 2023;959: 176076.
</cite> [<a href="https://doi.org/10.1016/j.ejphar.2023.176076" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37797675/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mei%20M,%20Tang%20L,%20Zhou%20H,%20et%20al.%20Honokiol%20prevents%20lung%20metastasis%20of%20triple-negative%20breast%20cancer%20by%20regulating%20polarization%20and%20recruitment%20of%20macrophages.%20Eur%20J%20Pharmacol.%202023;959:%20176076." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR68">
<span class="label">68.</span><cite>Liu L, Stokes JV, Tan W, Pruett SB. An optimized flow cytometry panel for classifying macrophage polarization. J Immunol Methods. 2022;511:113378.
</cite> [<a href="https://doi.org/10.1016/j.jim.2022.113378" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36265578/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20L,%20Stokes%20JV,%20Tan%20W,%20Pruett%20SB.%20An%20optimized%20flow%20cytometry%20panel%20for%20classifying%20macrophage%20polarization.%20J%20Immunol%20Methods.%202022;511:113378." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR69">
<span class="label">69.</span><cite>House IG, Savas P, Lai J, et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res. 2020;26:487–504.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-19-1868" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31636098/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?House%20IG,%20Savas%20P,%20Lai%20J,%20et%20al.%20Macrophage-derived%20CXCL9%20and%20CXCL10%20are%20required%20for%20antitumor%20immune%20responses%20following%20immune%20checkpoint%20blockade.%20Clin%20Cancer%20Res.%202020;26:487%E2%80%93504." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR70">
<span class="label">70.</span><cite>Tokunaga R, Zhang W, Naseem M, et al. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation—a target for novel cancer therapy. Cancer Treat Rev. 2018;63:40–7.
</cite> [<a href="https://doi.org/10.1016/j.ctrv.2017.11.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5801162/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29207310/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tokunaga%20R,%20Zhang%20W,%20Naseem%20M,%20et%20al.%20CXCL9,%20CXCL10,%20CXCL11/CXCR3%20axis%20for%20immune%20activation%E2%80%94a%20target%20for%20novel%20cancer%20therapy.%20Cancer%20Treat%20Rev.%202018;63:40%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR71">
<span class="label">71.</span><cite>Mercogliano MF, Bruni S, Mauro F, Schillaci R. Tumor necrosis factor-α blockade: an opportunity to tackle breast cancer. Front Oncol. 2020;10:584.
</cite> [<a href="https://doi.org/10.3389/fonc.2020.00584" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7189060/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32391269/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Mercogliano%20MF,%20Bruni%20S,%20Mauro%20F,%20Schillaci%20R.%20Tumor%20necrosis%20factor-%CE%B1%20blockade:%20an%20opportunity%20to%20tackle%20breast%20cancer.%20Front%20Oncol.%202020;10:584." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12369063/bin/12929_2025_1173_MOESM1_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12929_2025_1173_MOESM1_ESM.docx</a><sup> (105.8KB, docx) </sup><p>Additional file 1: Supplementary Fig. 1. The cell survival of MDA-MB-231, MDA-MB-453, and MDA-MB-468 was measured with Cell Proliferation Assay. IC50 values for abemaciclib were found to be 12.15, 2.86, and 8.01 μM for MDA-MB-231, MDA-MB-453, and MDA-MB-468 cells, respectively; and the corresponding cell survival curves were demonstrated. All experiments were performed three times.</p>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12369063/bin/12929_2025_1173_MOESM2_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12929_2025_1173_MOESM2_ESM.docx</a><sup> (235.2KB, docx) </sup><p>Additional file 2: Supplementary Fig. 2. The expression of retinoblastoma (RB) and phosphorylated (p)-RB in five triple-negative breast cancer cell lines treated with different conditions of abemaciclib and radiotherapy (RT) using western blot analysis. All experiments were performed three times. The quantification data are presented with mean ± standard deviation. Significance levels: * <em>P</em> &lt; 0.05; ** <em>P</em> &lt; 0.01; *** <em>P</em> &lt; 0.001; **** <em>P</em> &lt; 0.0001.</p>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12369063/bin/12929_2025_1173_MOESM3_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12929_2025_1173_MOESM3_ESM.docx</a><sup> (16.9MB, docx) </sup><p>Additional file 3: Supplementary Fig. 3. The gating strategy of tumor-infiltrating lymphocytes (TILs) in various treatments, including control, radiotherapy (RT), abemaciclib (Abe), anti-PD-L1 antibody (aPD-L1), Abe combined with aPD-L1, Abe combined with RT, aPD-L1 combined with RT, and the triple combination of Abe with aPD-L1 and RT. The M-MDSC gating strategy is listed separately.</p>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material4_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12369063/bin/12929_2025_1173_MOESM4_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12929_2025_1173_MOESM4_ESM.docx</a><sup> (11.5MB, docx) </sup><p>Additional file 4: Supplementary Fig. 4. Immunohistochemical staining of PD-L1 in tumors (EMT6 immunocompetent mouse model) following treatment with abemaciclib, radiotherapy (RT), and anti-PD-L1 antibody (aPD-L1). Tumors excised from treated mice were stained for PD-L1. (A)-(H) display PD-L1 across different treatment groups, including the control, RT alone, abemaciclib alone, aPD-L1 alone, and their combinations. Scale bar: 50 μm. (I) shows the quantification of PD-L1 staining, presented as the average number of cells per high-power field. Statistical significance was assessed using an unpaired two-tailed t-test. Significance levels: *** <em>P</em> &lt; 0.001; **** <em>P</em> &lt; 0.0001.</p>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material5_reqid_"><div class="media p"><div class="caption">
<a href="/articles/instance/12369063/bin/12929_2025_1173_MOESM5_ESM.docx" data-ga-action="click_feat_suppl" class="usa-link">12929_2025_1173_MOESM5_ESM.docx</a><sup> (63.6MB, docx) </sup><p>Additional file 5: Supplementary Fig. 5. Immunohistochemical staining of CD4 + T cells, CD8 + T cells, MCP-1 + , CD80 + , iNOS + , and CD206 + macrophages in tumors (EMT6 immunocompetent mouse model) following treatment with abemaciclib, radiotherapy (RT), and anti-PD-L1 antibody (aPD-L1). Tumors excised from treated mice were stained for CD4, CD8, MCP-1, CD80, iNOS, and CD206. The upper panel displays representative images of (A) CD4 + , (B) CD8 + , (C) MCP-1 + , (D) CD80 + , (E) iNOS + , and (F) CD206 + cells across different treatment groups, including the control, RT alone, abemaciclib alone, aPD-L1 alone, and their combinations. Scale bar: 50 μm. The lower panel quantifies the average number of (G) CD4 + T cells, (H) CD8 + T cells, (I) MCP-1 + cells, (J) CD80 + , (K) iNOS + , and (L) CD206 + cells per high-power field. Statistical significance was assessed using an unpaired two-tailed t-test. Significance levels: * <em>P</em> &lt; 0.05; ** <em>P</em> &lt; 0.01; *** <em>P</em> &lt; 0.001; **** <em>P</em> &lt; 0.0001.</p>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>No datasets were generated or analysed during the current study.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Journal of Biomedical Science are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s12929-025-01173-3"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/12929_2025_Article_1173.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (9.0 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12369063/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12369063/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12369063%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12369063/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12369063/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12369063/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40836337/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12369063/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40836337/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12369063/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12369063/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="0QL3M517jkxloHwg6QBSbe9IC3z5lELEXCM4gtaB47Bp4GGtv4yo2Odp3DYHgByr">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
